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Abstract 
Fibroblast growth factor (FGF) homologous factors (FHFs, FGF11-14) are a 
family of FGFs that are not secreted, nor activate FGF receptors.  Instead, they remain 
intracellular and bind to the voltage-gated Na+ channel C-terminus and modulate 
function.  Several lines of evidence, including data from heterologous expression 
systems and the distribution of FGF13 within the ventricular cardiomyocyte suggested 
that FHFs also modulate the CaV1.2 voltage-gated Ca
2+ channel.  The central 
hypothesis to this study is that FHFs modulate both voltage-gated Na+ and Ca2+ 
channels in the ventricular cardiomyocyte and therefore are loci for cardiac 
arrhythmia.  Using an adult ventricular cardiomyocyte system with adenoviral gene 
transfer, we manipulated the levels of FGF13 in the cell and performed 
electrophysiology, biochemistry and immunocytochemistry to analyze the effects on 
voltage-gated Ca2+ channel localization and function.  We showed that FGF13 is in 
complex with Junctophilin-2 and modulates CaV1.2 current density and localization to the 
T-tubule, leading to changes in Ca2+-induced Ca2+ release and ultimately a shortened 
ventricular action potential.  Through collaboration with the Mayo Clinic, a mutation in 
FGF12, the most highly expressed FHF in human ventricle was found in a patient with 
Brugada syndrome.  Using similar methodology, we determined that this mutation results 
specifically in a NaV1.5 loss of function with differential effects on CaV1.2 function, 
resulting in a Brugada-like ventricular action potential.  This data shows that FHFs are 
potent modulators of multiple ion channels and novel arrhythmogenic loci. 
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1. Introduction     
1.1 Sudden cardiac death: clinical significance 
Sudden cardiac death (SCD) is the leading cause of death in the developed 
world. Accounting for the deaths of more than 1 million people worldwide annually, it 
surpasses the total from lung and breast cancer, stroke, and acquired immune 
deficiency syndrome combined.1  SCD is also the leading cause of death in the United 
States of America, accounting for greater than 500,000 deaths per year.2   While the 
majority of cases of SCD are due to ischemic heart disease, SCD in the absence of 
structural heart disease typically occurs in a younger population of patients and is due to 
inherited or genetic disease.3  These electrical disturbances in the absence of heart 
disease point to an intrinsic defect in the electrical activity of the heart as driven by ion 
channels and have been termed “ion channelopathies.”  Inherited/genetic arrhythmias 
will be the focus of this thesis.  
1.2 The electrical activity of the heart 
Ion channels are integral membrane proteins that allow the conduction of ions 
across the cell membrane.  Ion channels drive the electrical activity of the heart, 
reflected in the sequential activation of cells in specialized, pacemaker regions of the 
heart and the propagation of electrical activity through the ventricles (Figure 1).  Intrinsic 
activity of the heart is initiated at the sinoatrial (SA) node and propagated through the 
atria to the atrioventricular (AV) node, where there is a brief pause.  Electrical activity 
then spreads through the bundle of His to the Purkinje fibers, through the septum, to the 
apex and working myocardium of the ventricles. 
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Figure 1: A schematic representation of the cardiac conduction system and 
the correlation between the action potentials of distinct regions of the heart with 
the surface electrocardiogram.  SVC, superior vena cava; IVC, inferior vena cava; 
RA, right atrium; RV, right ventricle; PA, pulmonary artery; LA, left atrium; LV, left 
ventricle; PV, pulmonary vein.  Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cardiology, Giudicessi JR, Ackerman MJ. 
Potassium-channel mutations and cardiac arrhythmias-diagnosis and therapy. 
9:319-332, copyright 2012.  
The gross electrical activity of the heart can be recorded non-invasively using the 
electrocardiogram (ECG, Figure 1, bottom).  The P-wave reflects SA node activity 
(yellow) leading atrial depolarization (green).  The PR interval (time between P and R 
wave) is the pause time within the AV node (orange).  Following this pause, ventricular 
depolarization occurs from the septum, to the apex and up to the ventricular walls, 
portrayed on the ECG as the QRS complex (blue).  Repolarization of the ventricle then 
occurs in the opposite direction to depolarization (T wave).  As shown in Figure 1, cells 
in each of these specialized regions excite through generation of action potentials. SA 
and AV nodal action potentials have a slow upstroke, whereas atrial and ventricular 
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action potentials have a fast upstroke and a plateau phase prior to returning to resting 
membrane potential.  This heterogeneity is a reflection of the different ion channels 
expressed in the different regions; SA and AV nodal action potentials are initiated by 
slow calcium (Ca2+) channels, whereas atrial and ventricular action potentials are 
initiated by fast sodium (Na+) channels (the details of which will be discussed in Sections 
1.2 and 1.3).  Because the plasma membrane, made up of a phospholipid bilayer, does 
not permit the movement of ions, ion channels are necessary to allow the conduction of 
ions between the inside and outside of the cell.  These ion channels also possess the 
property of voltage-dependence, allowing them to open in a particular order within the 
cell. The phospholipid bilayer acts to create a capacitor (a difference of charge 
separated by an insulator) because composition of the cytoplasm compared to the 
serum creates an electrical gradient in which the inside of the cell is negative compared 
to the outside.  Additionally, the concentrations of ions inside and outside the cell create 
chemical gradients.  For example, the positively charged cations, Na+ and Ca2+ are at 
very low concentrations inside the cell compared to the outside, in contrast to potassium 
ions (K+), which are highly concentrated inside the cell.  Using the Nernst equation, 
where S is an arbitrary ion with charge zs, R is the gas constant (8.3145 V C mol
-1 K-1), F 
is the Faraday constant (Nqe=9.6486 x 10
4 C mol-1), and the intracellular and 
extracellular concentration of S ([S]I and [S]E, respectively) is known, one can predict the 
reversal potential (Vs) of the ion and thus the direction of flow (into or out of the cell) at a 
given membrane potential.   
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Equation 1: Nernst Equation 
 
The complex integration of these ionic currents results in the cardiac action 
potential.  Here we will focus on the intricacies of the ventricular action potential, which 
has a different action potential waveform and different ion channel expression compared 
to the pacemaker SA and AV nodal cells (Figure 1).   
1.2.1 The ventricular action potential 
A more detailed view of the ventricular action potential can be seen in Figure 2. 
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Figure 2: The key ion channels in cardiac cells and their contribution to the 
cardiac action potential phases. Reprinted by permission from Macmillan 
Publishers Ltd: Nature. Marbán E., Cardiac channelopathies, 415;213-218, 
copyright 2002. 
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The cardiac ventricular action potential is divided into five phases, each of which 
is controlled by specific ion channels.  By convention, movement of positive current (I) 
into the cell is depicted as a negative deflection; outward movement of positive current is 
depicted as a positive deflection.  Phase 0 is the rapid upstroke of the action potential 
mediated almost entirely by voltage-gated Na+ channels (purple, SCN5A, NaV1.5), which 
allow Na+ to enter the cell down its electrochemical gradient, represented by a downward 
deflection. Phase 1 represents initial repolarization which occurs upon activation of 
rapidly activating and inactivating A-type K+ channels (green, KCND, KV4). The driving 
force for K+ is from the inside of the cell, to the outside, represented by a positive 
deflection in the current trace. The plateau phase, phase 2, occurs due to the slower 
activation and inactivation of inward Ca2+ current (orange, CACNA1C, CaV1.2) in 
response to depolarization, relative to the Na+ channel. Repolarization (phase 3) is 
mediated by multiple K+ channels, including those encoded by KCNH2 and KCNE2 
(HERG channel) and KCNQ1 forming the rapid (IKr) and slow (IKs) K
+ currents 
respectively (green).  The cell is maintained at its resting membrane potential (~ -85 mV) 
by the inward rectifying K+ channel encoded by KCNJ2 (green), represented as phase 4. 
1.2.2 Ca2+ is the ultimate transducer of electrical signals into 
physiologic function 
 The function of excitable cells such as neurons and cardiomyocytes is not just to 
produce electrical activity.  The electricity produced by ion channel activation needs to 
be translated into physiologic function.  This is accomplished through the activation of 
voltage-sensitive Ca2+ channels that allow the entrance of Ca2+ into the cell such that 
Ca2+ may act as a second messenger.   
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Changes in intracellular Ca2+ concentration in response to activation of voltage-
gated Ca2+ channels leads to many processes such as muscle contraction, 
neurotransmitter and hormone secretion, changes in gene expression and activation of 
signal transduction pathways.4  In the ventricular cardiomyocyte, activation of voltage-
gated Ca2+ channels does not only create the prolonged plateau phase.  Additionally, 
Ca2+ influx through voltage-gated Ca2+ channels increases Ca2+ inside the cell such that 
it can bind to and activate Ca2+ release channels in the sarcoplasmic reticulum (SR, a 
Ca2+ storage organelle).  This leads to an even greater release of Ca2+ from the SR, 
allowing Ca2+ to bind to troponin, leading to the activation of the myosin-ATPase in the 
contractile machinery of the muscle and the creation of tension, leading to contraction.  
This is termed excitation-contraction coupling and will be discussed in greater detail in 
Section 1.3.    
1.3 Voltage-gated ion channels 
1.3.1 Voltage-gated ion channel structure 
Voltage-gated ion channels are pore-forming structures within the plasma 
membrane. The principle subunits, so called α subunits (Figure 3), are composed of four 
homologous domains (I-IV).5, 6 Within each homologous domain there are six 
transmembrane α-helices (S1-S6) with intracellular N- and C- termini.4  
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Figure 3: Schematic of the voltage-gated ion channel structure.  It has four 
homologous domains (I-IV), each made up of six transmembrane segments.  S4 
represents the voltage sensors.  The channels have intracellular N- and C- termini. 
 While the α subunits of voltage-gated Na+  channels and voltage-gated Ca2+ 
channels are composed of one single peptide, encoding all 24 transmembrane 
segments, voltage-gated K+ channels are comprised of tetramers of α subunits that are 
homologous to an individual domain in a Na+ or Ca2+ channel.7-9  While not the focus of 
this thesis, Ca2+-activated K+ channels (KCa), cyclic nucleotide-gated channels (CNG), 
hyperpolarization-activated cyclic nucleotide-modulated (HCN) channels, and transient 
receptor potential (TRP) channels also share a similar structure to the voltage-gated K+ 
channels.  The simplest structural motif is within the inwardly rectifying K+ channel (Kir) 
in which the four subunits only have two transmembrane segments, M1 and M2, 
analogous to S5 and S6 in the other voltage-gated channels. 10, 11 When two of the pore 
motifs of Kir channels are linked together, they form the two-pore K+ channels.
12  
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The S5 and S6 segments along with the membrane re-entrant loop in between 
act as the selectivity filter and the pore.13-16  One of the first mammalian voltage-gated 
ion channels to be crystallized was the Kir channel, of which the M1 and M2 segments 
(equivalent to S5 and S6) form an “inverted teepee” arrangement around the central 
pore, with the outer mouth formed by the membrane re-entrant loop.17  Other channels 
that have been crystallized show a similar structure.18 
The S1 through S4 segments comprise the voltage-sensor of the channels.  In 
particular, the S4 segments have repeated motifs of one positively charged amino acid, 
followed by two hydrophobic residues.  These are thought to serve as the primary 
voltage sensors as mutations in the charged amino acids in particular have tremendous 
effects on gating.19, 20 It is still unclear how exactly this segment moves in response to 
voltage.21 However, it is known that the positive charges in these S4 segments respond 
to voltage change by movement that can be measured electrophysiologically as ~12 
positive charges translocated outwardly (a small positive deflection).22, 23 
While the transmembrane segments are critical for pore-formation, voltage-
sensing and selectivity, the intracellular N- and C- termini and loops between the 
domains confer modulation of channel function by post-translational modifications such 
as phosphorylation and by binding of small intracellular ligands such as β subunits, Ca2+, 
the Ca2+-sensing protein, calmodulin, and other modulators of trafficking and gating.  The 
function and modulation of voltage-gated Na+ and Ca2+ channels will be covered 
specifically in the two following sections. 
1.3.2 Voltage-gated Na+ channels 
The basic properties of voltage-gated Na+ channels, were described by Hodgkin 
and Huxley, beginning in 1952, when they were analyzing the action potential of the 
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squid giant axon using voltage clamp.24-27 They showed that nerve impulses are initiated 
by an inward current carried by Na+ in a voltage-dependent manner.  This Na+ current 
inactivates rapidly, in 1-2 milliseconds, and outward K+ current re-establishes the resting 
membrane potential. Soon after, Hille developed a model of the ion selectivity filter and 
how it specifically selects for Na+ through a dehydration of the ion through interaction 
with carboxyl side chains of the channel followed by rehydration in the pore lumen and 
exit into the cell.28  Additionally, Hille discovered that certain Na+ channels are the 
targets for local anesthetics such as lidocaine and that they bind the channel through the 
open activation gate.29 
The Na+ channel protein was discovered through purification with a scorpion 
toxin found to block the channel, which revealed a large, 260 kDa α subunit and smaller, 
30-40 kDa β subunits (Figure 4).  The topology of the Na+ channel is similar to other 
voltage-gated ion channels. Although the α subunit is sufficient to traffic to the 
membrane and generate current, the channel is typically associated with two β subunits.  
Each have a transmembrane domain and an immunoglobulin-like extracellular domain 
and can modulate trafficking and gating of the channel.30   
There are nine isoforms (NaV1.1-NaV1.9) of voltage-gated Na
+  channels, which 
upon membrane depolarization, initiate action potentials in neurons and skeletal and 
cardiac muscle.  They are divided generally into two groups based on their sensitivity to 
tetrodotoxin (TTX), first found in the puffer fish, Tetraodontidae, but later discovered in 
octopus, some frogs and newts.31     NaV1.5 (in cardiac muscle), and NaV1.8 and NaV1.9 
(found in dorsal root ganglion neurons) are all TTX-resistant channels and found on 
chromosome 3p21-24.32-34  These channels require micromolar concentrations of TTX 
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(compared to nanomolar for the TTX-sensitive) for blockade, however can be fully 
blocked by cadmium.35, 36   
In neurons, voltage-gated Na+ channels are concentrated in the axon initial 
segment.37 They are required to generate an action potential in the axon in response to 
neural input.38  Mutations in voltage-gated Na+ channels can lead to hyperexcitability 
(typically gain of function) or conduction failure (typically loss of function).  A paradoxical 
example of the effects of mutation on voltage-gated Na+ channels is a seizure disorder, 
called Dravet syndrome, which is due to a loss of function in NaV1.1.  NaV1.1 is found 
primarily in inhibitory neurons, therefore a loss of inhibitory neuron excitability leads to 
hyperexcitability of the post-synaptic neuron and seizures.    
In the heart, NaV1.5, encoded by SCN5A, predominates.  Localized to the 
sarcolemma and intercalated discs of the cardiomyocyte,39 NaV1.5 is responsible for the 
initiation of the action potential and propagation through the cardiac myocardium.  The 
“channelsome” of NaV1.5, reveals that Na
+ channels reside in subdomains that are 
defined by the presence of Ankyrin-G, a scaffolding protein, originally discovered in red 
blood cells, but found to be required for proper neuronal and cardiac ion channel 
localization.40, 41 Ankyrin-G binds to the Na+ channel on the intracellular loop linking 
domains II and III (Figure 4, blue).  Additionally, the C-terminal domain (CTD) of NaV1.5 
interacts with multiple proteins that modulate its function and targeting.  The crystal 
structure of the proximal CTD shows that calmodulin (CaM), which mediates the Ca2+ 
sensitivity of NaV1.5, binds to the NaV1.5 CTD distal to FGF13, a fibroblast growth factor 
(FGF) homologous factor (FHF).42-44  FHFs are intracellular FGFs (FGF11-14), bind to 
and modulate voltage-gated Na+ channels in brain, and we have shown how they 
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modulate NaV1.5 specifically in heart.  The role of FHFs in modulating cardiac Na
+ 
channel function will be discussed specifically in section 1.4. 
 
Figure 4: Schematic of the NaV1.5, the predominant cardiac Na
+ channel.  It 
is typically associated with two β subunits that interact with the intracellular N- 
and C-termini.  Two important proteins that interact with NaV1.5 are depicted at 
their interaction domains: Ankyrin-G (blue) at the II-III linker and FGF13 (red) at the 
C-terminus. Reprinted from Trends Cardiovasc Med, 211, Wei EQ, Barnett AS, Pitt 
GS, Hennessey JA, Fibroblast growth factor homologous factors in the heart: A 
potential locus for cardiac arrhythmias, 199-203, Copyright 2011. 
1.3.3 Voltage-gated Ca2+ channels 
Voltage-gated Ca2+ channels are the sine qua none of excitable cells-capable of 
translating electrical activity into cytoplasmic Ca2+ changes that regulate cellular 
responses such as neuronal activity, muscle contraction and hormone release.45   The 
electrical activity they create can shape and form action potentials.  For example, the 
pacemaker cells of the cardiac SA and AV node mentioned above only have HCN and 
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Ca2+ channels to generate the action potential.46, 47  In contrast, the ventricular 
cardiomyocyte utilizes the fast inward Na+ current to generate the rapid phase 0 upstroke 
of the action potential and the Ca2+ current to form the plateau phase because Ca2+ 
channels have a much slower onset of activation and inactivation – hundreds of 
milliseconds versus one millisecond for Na+ channels4 (see Figure 2 for schematic 
showing their relative contributions to the cardiac action potential). Voltage-gated Ca2+ 
channels are permeant to divalent cations such as Ba2+ and Sr2+, which are used in 
experimental settings. 
1.3.3.1 The voltage-gated Ca2+ channel superfamily 
Voltage-gated Ca2+ channels were first classified by the amount of depolarization 
required for activation and then further classified by their pharmacological sensitivities 
and genetic analysis (Figure 5).  In terms of their voltage-dependence of activation, one 
class only requires a small amount of depolarization to become activated, the low-
voltage activated (LVA) Ca2+ channels.  These channels also rapidly inactivate. In 
contrast, the second group, termed high-voltage activated (HVA) Ca2+ channels requires 
a large depolarization.  These channels tend to inactivate more slowly.48, 49 This contrast 
in activation allows one to hold the cell at depolarized potentials and isolate the HVA 
Ca2+ currents.  In Bean, 1985,50 cardiac atrial cells were used to decipher these two 
currents. The cells were bathed in micromolar concentrations of TTX and 115 mM Ba2+. 
If the cells were held at -30 mV (which inactivates LVA channels), no current was 
recorded with a step to -20 mV (not depolarized enough to activate HVA channels).  In 
contrast, with cells held at -30 mV and stepped to +10 mV, a large, inward, persistent 
current flowed, isolating the HVA currents.  The LVA currents could be elicited by 
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holding the cell at -80 mV (hyperpolarized such that neither currents are inactivated) and 
stepping to -20 mV.   
Further classification of HVA channels was done with pharmacologic differences 
between the channels. Cardiac, skeletal and smooth muscle, contain HVA channels that 
are dihydropyridine-sensitive.  They additionally have a very slow rate of inactivation.  
These dihydropyridine-sensitive HVA Ca2+ channels were termed L-type for large and 
long-lasting, of which there are four genes that encode them.  Muscle also contains LVA 
Ca2+ channels, which were termed T-type for tiny and transient, for which there are three 
genes.  Neurons contain other HVA Ca2+ channels that have much faster inactivation 
than L-type.  These are termed P/Q, N, and R type based on their pharmacology, with 
one gene for each, respectively.51 Figure 5 summarizes the homology, nomenclature 
and pharmacologic differences between the voltage-gated Ca2+ family.  
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Figure 5: Phylogeny of voltage-gated Ca2+ channel α subunits comparing 
the membrane-spanning segments and pore-loops (~350 amino acids).  They are 
divided by high-voltage activated (HVA) or low-voltage activated (LVA), then by 
their alphabetical names as in Tsien et. al., 1988.51 Further classification was done 
using pharmacology.  The α subunit protein name given is first its structural 
nomenclature and then the Snutch gene class.52  Pharmacologic information from 
Hille, 2001.4 Modified and reprinted from Neuron, Vol 25, Ertel EA, Campbell KP, 
Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, 
Birnbaumer L, Tsien RW, Catterall WA, Nomenclature of voltage-gated calcium 
channels, 533-535, Copyright 2000 with permission from Elsevier.  
HVA Ca2+ channels associate with subunits that are necessary for proper 
function (Figure 6). The first HVA  Ca2+ channel purified using H3-dihydrophyridine was 
the skeletal muscle CaV1.1, from which a total of  five  subunits were co-purified.
53  They 
were the α1 (~175 kDa, pore-forming subunit), α2 (~150 kDa), β (~54 kDa), δ (17-25 
kDa), and γ (~32 kDa).  It is now generally accepted that γ subunits play roles other than 
modulating Ca2+ channels.54 All subunits have been shown to enhance current density 
and affect kinetics in heterologous expression systems. The α2 and δ subunits actually 
are one gene, which is cleaved and re-ligated with disulfide bonds.  Thus, a reducing gel 
would show two separate bands.55, 56  β subunits are globular proteins that bind to an 18-
amino acid binding motif on the intracellular loop between domains I and II, termed the 
α-interaction domain (AID).57  They enhance functional expression of HVA Ca2+ channels 
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and have a major influence on the biophysical properties of the channel.  Generally 
speaking, they hyperpolarize the voltage-dependence of activation, and increase the 
maximum open probability resulting in increased macroscopic current.58, 59   There is 
debate as to whether the β subunit enhances current density through masking an 
endoplasmic reticulum signal in the α subunit or inhibiting proteosomal degradation, of 
which there is evidence for both.60, 61 Nonetheless, the β subunit is required for functional 
expression of HVA Ca2+ channels, in both heterologous expression systems and primary 
cells.   This thesis will focus primarily on the HVA, dihydropyridine-sensitive, L-type, 
CaV1.2 Ca
2+ channel, encoded by CACNA1C, and most highly expressed in the heart.   
 
Figure 6: A schematic of the voltage-gated Ca2+ channel and its associated 
subunits.  The β subunit binds the II-III linker.  The α2δ subunit has a small 
transmembrane segment and a large extracellular domain.   
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1.4 Voltage-gated Ca2+ channels translate electrical activity into 
physiologic function: focus on cardiac excitation-contraction 
coupling 
1.4.1 Physiology of Ca2+-induced Ca2+ release 
Excitable cells translate their electrical activity into action by Ca2+ fluxes 
modulated by voltage-sensitive, Ca2+-permeant channels. Therefore, Ca2+ acts as a 
second messenger to activate many cell functions. 4 The intracellular Ca2+ concentration 
[Ca2+]I is quite low, ranging from 30 to 200 nM such that when a Ca
2+ channel opens, 
there is a dramatic increase in [Ca2+]I (typically 10 μM).
62 This increase immediately 
activates those mechanisms to bring [Ca2+]I back to basal levels, such as pumps and 
buffers.  
In the heart, Ca2+ cycling is crucial for each beat, and the L-type CaV1.2 Ca
2+ 
channel is the primary mediator of excitation-contraction coupling.  Reviewed in Bers, 
200262 (Figure 7), upon depolarization, Ca2+ enters the cell in the form of Ca2+ current 
(ICa) from the outside through the CaV1.2, L-type Ca
2+ channel, creating the plateau 
phase of the action potential. This leads to Ca2+-induced Ca2+ release (CICR) from the 
SR through the juxtaposed ryanodine receptor (RyR).  This raises the [Ca2+]I, allowing 
Ca2+ to bind to troponin C on the myofilaments, activating the contractile machinery.  
Equally important is cardiac relaxation which requires machinery to decrease the [Ca2+]I 
back to baseline, leading to the dissociation of Ca2+ from the troponin C.  There are four 
pathways that remove Ca2+ from the cell: the sarcoplasmic-endoplasmic reticulum Ca2+ 
ATPase (SERCA), the sarcolemmal Na+/Ca2+ exchanger (NCX), sarcolemmal Ca2+ 
ATPase and the mitochondrial Ca2+ uniporter. 
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Figure 7: A schematic of the entire Ca2+ cycle in a ventricular 
cardiomyocyte. Inset shows the time course of an action potential, Ca2+ transient 
and contraction measured in a rabbit ventricular myocyte at 37 °C. NCX, Na+/Ca2+ 
exchange; ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic reticulum. 
Reprinted by permission from Macmillan Publishers Ltd: Nature, Bers DM, Jan 
10;415(6868):198-205, copyright 2002. 
1.4.2 Subcellular architecture: the dyad 
The juxtaposition of the CaV1.2 L-type Ca
2+ channel and RyR (about 12 μm) 
forms a dyad (see Figure 8) and is crucial for CICR from the SR.  The opening of one 
local L-type Ca2+ channel in each couplon (a single CaV1.2 juxtaposed to multiple RyR), 
leading to two to four Ca2+ ions binding to RyR, is sufficient to activate full Ca2+ release 
at that couplon.  Coupled gating between RyRs or high local Ca2+ (> 10 μM) leads to the 
activation of neighboring RyRs.62   
Confirmed by electron microscopy,63 ventricular cardiomyocytes contain 
transverse tubules (T-tubules), which are invaginations of the sarcolemmal membrane in 
the transverse direction. These invaginations to the center of the cell explained how it 
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takes less than 40 ms for excitation to travel from the external membrane to the center of 
the cell, about 50 μm.64 Ca2+ channels are enriched in the T-tubules – about three to 
nine fold higher than the surface sarcolemma.65 The T-tubules bring the CaV1.2, L-type 
Ca2+ channels in direct juxtaposition with RyR in the SR to form the dyad.   
 
Figure 8: A schematic depicting the cardiac dyad composed of the ryanodine 
receptor (RyR) in sarcoplasmic reticulum (SR) juxtaposed to the CaV1.2 Ca
2+  
channel in the T-tubule.  Junctophilin-2 (JPH2) mediates the distance between the 
two membranous structures.66 JPH2 contains four domains, the most N-terminal 
contains eight membrane occupation recognition nexuses (MORN), followed by an 
α-helix, the divergent region and a transmembrane domain (TMD) through the SR. 
Reprinted with permission from Wolters Kluwer, Circ Res, Hennessey JA, Wei EQ, 
Pitt GS. Fibroblast growth factor homologous factors modulate cardiac calcium 
channels, [Epub ahead of print] June 26. copyright 2013. 
Interestingly, T-tubules are absent in neonatal cardiomyocytes, and appear to be 
regulated by the load on the heart, as well as biochemical factors.  Two molecules 
responsible for some regulation of the T-tubules that I would like to focus on are BIN1 
(amphiphysin 2) and junctophilin-2 (JPH2).    
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BIN1, a member of the BAR domain family of proteins, invaginates membranes 
into narrow tubules.67 Even when expressed ectopically in non-muscle cells, it causes 
tubular formation and has been shown to be concentrated at the sites of developing T-
tubules.68  Additionally, BIN1 has been shown to be crucial for trafficking the CaV1.2 L-
type Ca2+ channel to the T-tubule69 and decreases in BIN1 have been associated with 
detubulation, decreased CaV1.2 trafficking, and heart failure.
70   
JPH2 promotes junction formation between the T-tubule and SR.71 As shown in 
Figure 8, JPH2 is capable of binding to the T-tubule plasma membrane via membrane 
occupation recognition nexus of which there are eight, and has a transmembrane 
domain through the SR.  In between the two membrane binding motifs, there is an α 
helix thought to be responsible for the proper spacing between the T-tubule and SR, and 
a divergent region which varies among the four isoforms of JPH and is thought to 
mediate intracellular protein-protein interactions.66  Loss of JPH2 leads to disruption of 
the dyad architecture, leading to deficiencies in CICR, and dilated cardiomyopathy.72  
Additionally, changes in JPH2 levels have been associated with heart failure,73 and 
mutations in JPH2 cause hypertrophic cardiomyopathy.74 
1.5 Fibroblast growth factor homologous factors1 
Fibroblast growth factor (FGF) homologous factors (FHFs) are a subset of the 
FGF family.75  Composed of four genes (FGF11-FGF14), FHFs were cloned by 
                                               
1
 Following an article published in Circulation Research (Wang et. al., 2011) in which we were the first to 
describe the endogenous role of fibroblast growth factor homologous factors in the heart, we were invited by 
Elizabeth G. Nabel, Editor-in-Chief for Trends in Cardiovascular Medicine to write a review of the current 
state of knowledge of FHFs in the heart and the questions that still surround them.  This section is largely 
based on this review for which I was the supervising author. 
 
Reprinted from Trends Cardiovasc Med, 211, Wei EQ, Barnett AS, Pitt GS, Hennessey JA, Fibroblast 
growth factor homologous factors in the heart: A potential locus for cardiac arrhythmias, 199-203, Copyright 
2011. 
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homology after FHF1 (FGF12) was first identified in a screen for novel genes expressed 
in the retina.76 For each FHF, multiple isoforms with distinct N-terminal sequences are 
produced through alternative promoter usage and alternative splicing, yielding 10 FHF 
isoforms in humans.77 Unlike canonical FGFs, FHFs lack signal sequences, are not 
secreted, and do not bind to or activate FGF receptors. Rather, these intracellular 
proteins bind to and modulate voltage-gated Na+ channels.78  
The four mammalian FHFs bind directly to the CTD of voltage-gated Na+ 
channels,78-81  and different FHF isoforms differentially modulate Na+ channel function.82, 
83 In neurons, FHFs are concentrated at the AIS with voltage-gated Na+ channels and 
play a role in Na+ channel localization to the AIS and neuronal excitability.  FHF 
dysfunction alters Na+ channel behavior in the nervous system and has been implicated 
in neurologic disease.84, 85  Spinocerebella ataxia 27 (SCA 27) is caused by a missense 
mutation in FGF14 due to decreased Na+ channels at the AIS leading to decreased 
neuronal excitabilty.86  In addition, nonspecific forms of X-linked mental retardation have 
been mapped to the FGF13 locus, suggesting that the FGF13 gene may be a candidate 
for these disorders.87 
1.5.1 FGF13 is the predominant cardiac FHF in mice and rats 
Although all FHFs are highly expressed in the nervous system and developing 
heart,76 the expression profile of FHFs in adult cardiomyocytes remained unclear until 
recently.78 Quantitative reverse transcriptase-polymerase chain reaction with isoform-
specific primers showed that FGF13 is the most abundant FHF in adult mouse and rat 
cardiomyocytes and that other FHF genes are expressed at relatively low levels.  
Specifically, FGF13-VY is the most highly expressed of all the FGF13 splice variants. 
Furthermore, only FGF13 could be detected by Western blot of mouse cardiomyocyte 
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lysate. These results are consistent with a recently published expression atlas of the 
FGF system in adult mouse showing high levels of FGF13 in the heart and low levels of 
other FHFs.88  The expression patterns of FHFs in human heart have not been reported 
and may be different from those in mouse.  
1.5.2 FGF13 binds to NaV1.5 directly in murine cardiomyocytes  
FGF13, in addition to being the predominant cardiac FHF, directly binds NaV1.5, 
the principal cardiac Na+ channel α subunit.78 FGF13 coimmunoprecipitated with NaV1.5 
from mouse cardiomyocyte lysates, suggesting that FGF13 and NaV1.5 are in the same 
complex. An in vitro binding assay utilizing the NaV1.5 CTD and lysates expressing 
specific FGF13 isoforms indicates that this interaction is likely direct and that the CTD of 
the NaV1.5 binds to the core of FGF13. Data from surface plasmon resonance 
spectroscopy also support the hypothesis that the Na+ channel α subunit CTD and 
FGF13 core region interact directly.43, 79, 81 The crystal structure of a ternary complex of 
the NaV1.5 CTD, FGF13, and calmodulin confirmed this direct interaction and 
demonstrates that FGF13 binds to the globular domain of the Nav1.5 CTD, and residues 
distal to Ser1885 on NaV1.5 contribute significantly to the FHF interaction site on 
NaV1.5.
43 Furthermore, immunocytochemistry shows that a portion of FGF13 colocalizes 
with NaV1.5 at the lateral membrane and intercalated disks in cardiomyocytes, two 
regions with distinct NaV1.5 populations.
78, 89  
1.5.3 FGF13 modulates Na+ channel current density and kinetics in 
cardiomyocytes 
The effect of FHF-Na+ channel α subunit binding on channel properties has been 
widely studied in heterologous expression systems and neurons. In these settings, FHF 
binding modulates Na+ current density, channel availability, and channel expression and 
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localization, the degree to which varies depending on the FHF isoform and Na+ channel 
α subunit.82-84  
The function of FHFs in cardiomyocytes and their role in the modulation of 
endogenous Na+ currents have not been studied until recently.78 Knockdown of FGF13 
by infection of adult mouse ventricular cardiomyocytes with an adenovirus expressing a 
shRNA to all FGF13 splice variants reduced peak Na+ current density by 49%. 
Knockdown of FGF13 did not alter NaV1.5 total protein or mRNA levels. However, 
surface NaV1.5, measured by surface biotinylation, was reduced by 45%. In addition, 
FGF13 knockdown hyperpolarized the steady-state inactivation curve and delayed 
channel recovery from inactivation, further reducing channel availability (Figure 9). 
Together, these data suggest that FGF13-NaV1.5 binding is necessary for proper Na
+ 
channel function in cardiomyocytes. 
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Figure 9: Illustration of FGF13 regulation of NaV1.5 gating kinetics and 
membrane trafficking in wild-type (WT) cardiomyocyte (left) and FGF13 
knockdown cardiomyocyte (right). Binding of FGF13 to the C-terminus of NaV1.5 
modulates the voltage dependence of channel inactivation. FGF13 knockdown 
reduces the number of channels available to be activated: In the patch of 
sarcolemma illustrated, one of three channels is activated in the knockdown 
cardiomyocyte compared to four of five channels in WT cardiomyocyte. FGF13 is 
also required for proper trafficking of channels to the membrane: In the 
knockdown, only three of five channels are expressed at the membrane. 
Collectively, the reduced channel availability and surface expression lead to 
reduced current density. Furthermore, in the knockdown, delayed recovery from 
inactivation slows conduction velocity through cardiac tissue, providing a 
possible substrate for re-entrant arrhythmias. Reprinted with permission from 
Trends Cardiovasc Med, 211, Wei EQ, Barnett AS, Pitt GS, Hennessey JA, 
Fibroblast growth factor homologous factors in the heart: A potential locus for 
cardiac arrhythmias, 199-203, Copyright 2011. 
 
1.6 Mutations in ion channels and their modulators lead to 
cardiac arrhythmia 
Action potentials are shaped by the ion channels that contribute to them.  
Channelopathies can result from genetic mutation or malfunction of one or many ion 
channels within the cell.  Genetic channelopathies can be a result of mutations in the 
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channel pore-forming subunits or a modulatory protein. The first cardiac channelopathies 
were identified in patients with congenital long QT syndrome (LQTS), in which mutations 
were found in the pore-forming subunits of voltage-gated K+ channels.90 
Channelopathies are responsible for about 50% of the sudden arrhythmic death 
(SAD) cases.91 The two most prevalent congenital channelopathies are LQTS and 
Brugada Syndrome (BrS).92 
1.6.1 Long QT Syndrome 
Long QT syndrome is so named because it results in a prolonged QT interval on 
the surface ECG (Figure 10A, B). The QT interval is primarily determined by the action 
potential duration in the ventricular cardiomyocyte, and a prolonged QT interval typically 
occurs due to a reduction in repolarizing (typically K+) currents or gain of function 
mutations in depolarizing (typically Na+ and Ca2+) currents.93   
1.6.1.1 Genetics 
The three most common mutations in LQTS are found in K+ channels, KCNQ1 
(encoding KvLQT1, IKs) and KCNH2 (encoding HERG, IKr), and the voltage-gated Na
+ 
channel, SCN5A (encoding NaV1.5).  Additionally, Timothy syndrome is a rare form of 
congenital LQTS caused by mutations in CACNA1C (encoding CaV1.2). Auxiliary 
subunits to the ion channels listed above such as β subunits, as well as proteins 
responsible for structure and trafficking such as ANK2, encoding Ankyrin-B and SNTA1, 
encoding α1-syntrophin have also been shown to be loci for LQTS.
92 
1.6.1.2 Pathophysiology 
The mechanism through which these mutations might lead to disease is quite 
diverse, ranging from changes in intrinsic channel function (increased channel 
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availability, for example in the depolarizing currents), to proteosomal degradation or 
retention in the endoplasmc reticulum for the K+ channels leading to decreased cell 
surface expression and decreased repolarization force.  
For example, Timothy syndrome is characterized by a mutation in CACNA1C 
which leads to a loss of channel voltage-dependence of inactivation. A prolonged Ca2+ 
current leads to a longer phase 2 of the action potential (Figure 10A and B), leading to a 
prolonged QT interval.94 
Clinically, a prolonged QT interval, predisposes patients to early after 
depolarizations (so called R on T phenomenon on ECG, Figure 10C), which can lead to 
a type of polymorphic ventricular tachycardia called torsades de pointes, ventricular 
fibrillation and SCD.92  
 
Figure 10: Mechanism of prolonged QT interval in LQTS.  A prolonged 
action potential (A) results in an increased time necessary to repolarize the cell 
back to resting membrane potential, leading to a prolonged QT interval on ECG, B. 
Reprinted from Gene, Vol 517, Abriel H, Zaklyazminskaya EV. Cardiac 
channelopathies: Genetic and molecular mechanisms, 1-11, Copyright 2013, with 
permission from Elsevier. C, a prolonged QT interval creates a susceptibility 
window during which an extrasystole can lead to torsades de pointes.  Reprinted 
and with permission from John Wiley and Sons, J Cardiovasc Electrophysiol, 
Molecular and electrophysiological bases of catecholaminergic polymorphic 
ventricular tachycardia, Mohamed U, Napolitano C, Priori SG. 18:791-797, 
Copyright 2007. 
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1.6.2 Brugada syndrome 
BrS is characterized by ST-segment elevation in the right precordial leads > 2 
mm, pseudo right bundle branch block and T-wave inversion with an increased risk of 
SCD due to ventricular tachycardia.95  
1.6.2.1 Genetics 
BrS is typically inherited in an autosomal dominant manner, but many patients do 
not have a family history of BrS or SCD, making de novo mutations or incomplete 
penetrance possible.96 Mutations in the SCN5A gene account for 15-30% of all BrS 
cases.97 More recently, mutations in CACNA1C and its auxiliary subunits have also been 
implicated for a small portion of BrS.98 Other proteins known to traffic voltage-gated Na+ 
channels, such as MOG1 have also recently been implicated.99 
1.6.2.2 Pathophysiology 
Mutations in SCN5A or its trafficking proteins that lead to BrS are due to a loss of 
function of the NaV1.5 Na
+ channel.  This can be due to a decrease in channel 
availability or a decrease in the amount of channel at the cell surface.  Similar loss of 
function is observed in BrS patients due to CaV1.2 loss of function. It is believed that this 
decrease in depolarizing currents leads to ST-segment elevation due to the higher 
expression of the repolarizing Ito KV4 K
+ channel in the right ventricular epicardium 
compared to the endocardium. In a normal heart, there is little to no transmural (between 
epicardium and endocardium) voltage gradient (Figure 11A), even with higher epicardial 
KV4 expression. However, accentuation of the epicardial action potential notch due to 
loss of depolarizing Na+ or Ca2+ currents creates a larger transmural voltage gradient 
between the epicardium and endocardium, leading to ST-segment elevation in the form 
of a J-wave (Figure 11B).  Additionally, this is typically heterogeneous within the 
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epicardium itself, leading to some cells with a complete loss of their dome and others 
that have delayed activation of the channels responsible for phase 2 and 3.   This leads 
to dispersion of repolarization within the epicardium as well as a dispersion of 
repolarization between the epicardium and endocardium (transmural dispersion).  This 
creates a vulnerable window during which an extrasystole can induce a re-entrant 
arrhythmia leading to ventricular tachycardia.    
Because of this potential for re-entrant arrhythmia, patients with BrS have an 
increased risk for SCD.  The majority of life-threatening arrhythmias develop during rest 
or sleep, or during routine daily activities.  Additionally, fever and some medications can 
also provoke syncopes and cardiac arrest.100, 101 
 
Figure 11: Schematic representation fo the right ventricular epicardial and 
endocardial action potential and the changes in the epicardial action potential that 
are though t to underly the electrocardiographic findings of BrS. Reprinted and 
with permission from John Wiley and Sons, J Cardiovasc Electrophysiol, The 
Brugada syndrome: ionic basis and arrhythmia mechanisms, Antzelevitch C, 
Feb;12(2):268-72, copyright 2001.  
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1.6.3 FHFs may be unidentified loci for cardiac arrhythmias2  
The alterations in NaV1.5 sarcolemmal expression and gating kinetics induced by 
FGF13 knockdown suggest that FHF loss-of-function mutations may be unrecognized 
causes of cardiac arrhythmias associated with Na+ channel loss of function. In addition, 
mutations in the gene encoding SCN5A that disrupt FHF interaction may produce 
equivalent effects as FHF loss-of-function mutations. FGF13 knockdown in mouse 
provides a model for studying potential loss-of-function mutations in cardiac FHFs, which 
may promote arrhythmogenesis via a combination of several mechanisms: (1) reduced 
trafficking of NaV1.5 to the plasma membrane; (2) reduced channel availability; and (3) 
delayed recovery from inactivation, leading to (4) decreased conduction velocity (Figure 
9). 
Na+ channel dysfunction is central to LQTS and BrS. LQTS type 3 arises from 
mutations in SCN5A that disrupt fast inactivation of NaV1.5, increasing inward sodium 
current and thereby prolonging the QT interval.102 Moreover, in recent years, mutations 
in genes encoding NaV1.5 regulatory proteins have been discovered as new loci for 
cardiac arrhythmias. For instance, congenital LQTS types 9, 10, and 12 are linked to 
mutations in CAV3 (caveolin-3), SCN4B (β subunit 4 of sodium channel), and SNTA1 
(α1-syntrophin), respectively, all of which lead to an increase in NaV1.5 persistent 
current.103-105  
                                               
2
 Following an article published in Circulation Research (Wang et. al., 2011) in which we were the first to 
describe the endogenous role of fibroblast growth factor homologous factors in the heart, we were invited by 
Elizabeth G. Nabel, Editor-in-Chief for Trends in Cardiovascular Medicine to write a review of the current 
state of knowledge of FHFs in the heart and the questions that still surround them.  This section is largely 
based on this review for which I was the supervising author. 
 
Reprinted from Trends Cardiovasc Med, 211, Wei EQ, Barnett AS, Pitt GS, Hennessey JA, Fibroblast 
growth factor homologous factors in the heart: A potential locus for cardiac arrhythmias, 199-203, Copyright 
2011. 
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Although no mutations in FHFs have yet been associated with inherited 
arrhythmias, it is possible that FHF dysfunction in cardiomyocytes may disrupt fast 
inactivation of cardiac Na+ channels, serving as an additional, yet unidentified locus for 
LQTS. It has been speculated that overexpression of FHFs above their endogenous low 
levels in the heart may produce physiological changes similar to those of LQTS.106 The 
recent crystal structure of the FGF13 binding sites on NaV1.5 suggests that FGF13 binds 
in a region of the CTD that contains a D1839G mutation associated with LQTS.43, 107 This 
mutation may alter interaction with a knob formed by a conserved asparagine on FHFs, 
possibly affecting the affinity of FHF binding. Thus, it is possible that mutations at sites 
on either the FHF or NaV1.5 CTD binding surfaces may produce a LQTS phenotype. 
Of note, Liu et al. previously reported that a D1790G LQTS mutation abolished 
binding of FGF12B to the NaV1.5 CTD.
106, 108 However, according to our recent crystal 
structure, the aspartate at 1790 does not contribute to the critical residues that form the 
FHF binding surface. Given that the interaction motif is conserved among NaV1.x CTD-
FHF pairs,43  it is unlikely that FGF12B binds at a site different from FGF13; the 
identification of aspartate 1790 as a contributor to FHF binding may have been due to 
the use of a sensitive but not specific yeast two-hybrid method that used indirect 
assessment of interaction to perform the binding site mapping experiment. 
BrS is often associated with a decrease in peak Na+ current due primarily to 
NaV1.5 biophysical defects.
109 Given that only approximately 20% of BrS cases to date 
have defined genetic defects,109  FHF mutations may be unexplored loci for the loss of 
NaV1.5 channel function. Mechanisms for the decrease in current density include (1) 
reduced expression of the channel; (2) a shift in voltage or time dependence of 
activation, inactivation, or reactivation; and (3) accelerated or prolonged recovery from 
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inactivation. FHF dysregulation may contribute to the pathogenesis of BrS through many 
of these mechanisms.110  The FGF13 knockdown data suggest that FHF loss-of-function 
mutations may reduce current density by decreasing channel surface expression and 
causing a hyperpolarizing shift in inactivation. Furthermore, one of the hallmarks of 
Brugada syndrome—slowed conduction—could be explained by delayed Na+ channel 
recovery from inactivation. FHF loss-of-function mutations may lower the threshold of 
heart rate for which voltage-gated Na+ channels can fully recover, decreasing conduction 
velocity and maximum capture rate and providing a substrate for ventricular 
tachycardia/ventricular fibrillation and re-entrant arrhythmias. 
In addition to modulating channel gating kinetics, FHFs play an important role in 
proper trafficking of Na+ channels to the cell membrane. In neurons, FGF14 appears to 
participate in targeting voltage-gated Na+ channels to the AIS: Expression of an FGF14 
SCA 27-causing dominant negative mutant abolished binding of wild-type FGF14 to 
NaV1.2 and reduced targeting of Na
+ channels to the AIS.84 In the heart, FGF13 appears 
to play an analogous role in targeting sodium channels to the sarcolemma because 
knockdown of FGF13 is associated with reduced surface expression of NaV1.5. Just as 
FHF mutations in the central nervous system impair neuronal excitability, mutations of 
FHFs in the heart, in addition to altering channel biophysical properties, may reduce 
cardiac excitability by disrupting channel membrane trafficking. It is unclear whether 
FGF13-mediated trafficking requires direct binding between FGF13 and the NaV1.5 CTD 
or whether FGF13 acts in an integrated manner with other channel modulators. Because 
numerous modulatory proteins as well as the NaV β subunits also bind to the NaV1.x 
CTD and regulate channel trafficking,111 it is conceivable that FHFs may work in concert 
 32 
with those other trafficking proteins. Laezza et al. (2007)84 speculate, for instance, that 
FHFs may modulate interaction between the Na+ channel α and β subunits.  
FHFs appear to be similar in function to ankyrins, which are adapter proteins 
responsible for proper expression and localization of ion channels and transporters in 
excitable and nonexcitable cells.112 Ankyrin-B (ANK2) and Ankyrin-G (ANK3) are the two 
predominantly expressed isoforms in the heart. Ankyrin-G binds to NaV1.5 at a motif in 
the linker loop between domains II and III (Figure 4);113 no direct interaction has been 
found between Ankyrin-B and NaV1.5. Genetic variants in ANK2 have been linked to 
LQTS type 4, also known as “Ankyrin-B syndrome,” an atypical arrhythmia with risk of 
sudden cardiac death.112 In addition, a mutation in the consensus sequence in NaV1.5 
for binding to Ankyrin-G has been associated with BrS.114 This mutation reduced surface 
expression of NaV1.5 in cardiomyocytes and affected channel gating behavior in a 
heterologous expression system, suggesting that Ankyrin-G may modulate gating 
properties, in addition to its role in trafficking Na+ channels to the cell membrane.114 In a 
similar manner, mutations in the sequences encoding the CTD of NaV1.5 may abolish 
FHF binding, leading to reduced channel surface expression and abnormal gating 
properties. Whether FHFs and ankyrins interact to regulate channel activity remains 
unclear and merits further investigation. 
It is likely that FHFs play other important roles in cardiomyocytes that have yet to 
be explored. Immunocytochemistry shows that FGF13 exhibits a widespread expression 
pattern in ventricular cardiomyocytes, including a punctate distribution in the cytoplasm 
and prominent nuclear localization.78 Of particular interest for future investigation are 
potential interactions between FHFs and other cardiac ion channels. 
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2. Exploring the role of FHFs in cardiac physiology in 
the native ventricular cardiomyocyte: Methodology 
 
In this section, I will explain the methodology of isolation of ventricular 
cardiomyocytes, adenoviral production and expression, and electrophysiology – the 
central experiments behind the data I will be describing in Chapters 3 and 4.  For much 
of the optimization of these protocols, I worked with Chuan Wang, a postdoctoral fellow 
in the laboratory of Geoffrey Pitt.  With this methodology, we published a paper on 
FGF13 modulation of NaV1.5 function in ventricular cardiomyocytes.  Some of the data 
shown in this Chapter to validate the methods derive from this paper.   
 
Wang C, Hennessey JA, Kirkton RD, Wang C, Graham V, Puranam RS, 
Rosenberg PB, Bursac N, Pitt GS. Fibroblast growth factor homologous factor 13 
regulates Na+ channels and conduction velocity in murine hearts. Circ Res. 
2011;109:775-782. 
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2.1 Introduction 
Ion channels are not just single protein moieties, stuck in the membrane in 
isolation.  Instead, as more data emerges, it is clear these channels are surrounded by a 
large complex of modulatory and scaffolding proteins, termed the “channelsome.”  
Indeed, an interaction proteomics screen of the neuronal pre-synaptic Ca2+ channels 
using affinity purification and mass spectroscopy showed there are ~200 proteins within 
the nanoenvironment of these channels.  Additionally, using quantitative mass 
spectroscopy, they showed that these proteins vary in abundance, stability of assembly 
and preference for a specific pre-synaptic Ca2+ channel.54   Furthermore, many 
modulatory proteins are part of multiple ion channels’ nanoenvironment.  Take for 
example the Ca2+ sensor, calmodulin, that binds to and modulates Ca2+ sensitivity of 
Na+, Ca2+, and K+ channels.43, 115, 116   
The cardiomyocyte consists of multiple nanoenvironments.  The intercalated disc 
is defined by the presence of gap junctions made up on Connexin 43 and voltage-gated 
Na+ channels so that electrical activity can conduct through the myocardium.117  The 
sarcomere is its own nanoenvironment, which houses the contractile filaments and a 
whole host of modulators.118  The SR is responsible for storing Ca2+.  Proteins in the SR 
are capable of releasing that Ca2+ as well as sensing the levels within that 
compartment.118  Finally, the T-tubules, a necessary structure for efficient CICR, house 
CaV1.2 Ca
2+ channels, NCX, and the Na+/K+ ATPase.119  Within each of these 
nanoenvironments, there are proteins specific to the region and required for proper 
function of that region.   
Investigators in the past when identifying ion channel modulators have ignored 
the other components of the cardiomyocyte and performed experiments of channel 
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function in a heterologous expression system – one channel with one modulator.  What 
is becoming clearer as more ion channel modulators are identified as loci for inherited 
arrhythmias is that they are not portraying the whole picture in using those systems.  
Indeed, even twenty years after the discovery of the beta-adrenergic modulation of 
voltage-gated Ca2+ channels, it was only recently that one could recapitulate this 
mechanism in a heterologous expression system,120 and still with some controversy.121  
This is one of many examples of data suggesting that heterologous expression systems 
do not provide a sufficient environment for all cellular physiologic processes.   
There are many examples of channel modulators that play multiple roles, 
providing further evidence that the transfection of one type of channel with one type of 
modulator into a HEK293T cell does not accurately replicate the physiology of an 
excitable cell.  For the FHFs, this has been a theme throughout the studies of their role 
in modulating voltage-gated Na+ channels in neurons; investigators have reported 
opposing effects when comparing heterologous expression systems to primary neuronal 
culture (Figure 12).82  Lou et. al.82  compared the current densities elicited either in a 
heterologous expression system with FGF14 overexpressed with Nav1.1 to that of a 
primary hippocampal neuron with FGF14 overexpression.  Specifically, FGF14-B 
(labeled as FGF14-1b in Figure 12), decreases current density when co-expressed with 
Nav1.1 (Figure 12, top) and with NaV1.5 (not shown) and in Neuro-2A cells, a neuronal 
cell line.82 In contrast, when FGF14-B is overexpressed in a primary hippocampal 
neuron, it increases current density above the basal level (Figure 12, bottom).  This 
epitomizes the opposing effects on Na+ channel function observed between 
heterologous expression systems and primary cells.   
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Figure 12: Comparison of effects of FHFs on Na+ channel function in 
heterologous expression system versus neurons.  Note that in a heterologous 
expression system, FGF14-1b decreases current density (top) while in 
hippocampal neurons, it increases current density compared to control. Modified 
and reprinted with permission from John Wiley and Sons, J Physiology, Lou JY, 
Laezza F, Gerber BR, Xiao M, Yamada KA, Hartmann H, Craig AM, Nerbonne JM, 
Ornitz DM. Fibroblast growth factor 14 is an intracellular modulator of voltage-
gated sodium channels, 569:179-193, copyright 2005.  
Our lab has seen similar discrepancies between heterologous expression 
systems and cardiomyocytes.  As shown in Figure 9, Section 1.3.3, knockdown of 
FGF13 in ventricular cardiomyocytes reduces NaV1.5 current density.  However, when 
one co-expresses various FGF13 splice variants with NaV1.5 in a HEK293 cell, the 
current density is also reduced (data by Chuan Wang, 2009, see Chapter 4).  This again 
demonstrates that studying these modulatory proteins in heterologous expression 
systems does not accurately describe their roles in native cells. 
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Therefore, to elucidate the true physiologic effects of FHFs on cardiac function, I 
came up with a strategy to study FHFs in their native environment.  We used isolated 
adult ventricular cardiomyocytes and manipulated their genetic environment with 
adenoviral gene transfer of shRNA or FHF genes.  To study the electrophysiologic 
effects of FHFs on channel function, we used whole-cell patch clamp.  These methods 
are summarized in the following sections.      
2.2 Isolation and culture of ventricular cardiomyocytes using a 
Langendorff apparatus 
2.2.1 Introduction 
To eliminate the confounding data from heterologous expression systems, for the 
following studies, I designed a cardiomyocyte culture system in which I could knockdown 
endogenous FGF13 (as shown in Wang et. al., 2011),78 and rescue it with various 
FGF13 splice variants and other FHF isoforms.  To be able to successfully infect 
cardiomyocytes with multiple viruses, I needed to come up with a way to not only isolate 
cardiomyocytes with minimal ischemic time, but also be able to keep them in culture 
such that the viruses could exert their genetic effects on the cell.  
2.2.2 Materials and Methods 
C57/Bl6 mice or Sprague-Dawley rats, age 6 to 8 weeks old, are initially 
anesthetized with 250 mg/kg tribromoethanol (Sigma) and anti-coagulated with 8,000 
units/kg Heparin (Sigma) intraperitoneally (IP).  Following induction of anesthesia 
(usually 2 to 5 minutes), another 8,000 units/kg Heparin is given IP to ensure full anti-
coagulation of the coronary vessels.  After another three minutes, the body is wiped with 
70% ethanol and a bilateral thoracotomy performed.  The heart is removed, taking care 
to leave the aorta and at least the first branch (the brachiocephalic artery) intact for 
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proper cannulation and placed in a cold bath of Ca2+-free basal isolation solution (BIS, 
see Table 1 for recipe).  This provides cardioplegia (paralysis of the heart) through a 
decrease in temperature and a lack of extracellular Ca2+.  The heart is then moved to a 
second, cold bath of BIS and placed under the dissecting microscope for cannulation of 
the aorta.  The aorta is tied onto the cannulus using 5-0 suture.  When performing 
isolations of rat ventricular cardiomyocytes, if the aorta was too large for the cannula, the 
distal aorta would be tied off and the brachiocephalic artery cannulated.  To ensure both 
coronary arteries are being perfused, the cannula is attached to a syringe containing BIS 
and the BIS is slowly pushed into the heart using the plunger.  Washout of the blood 
from the coronary vessels ensures 1) that the proper vessel (the aorta) was cannulated 
and 2) the cannula is not blocking either the left or right coronary artery coming off the 
aorta.  
Following confirmation of proper cannulation, the heart is hung on a Langendorff 
apparatus (Figure 13).  A Langendorff apparatus is a glass tube encased in a water 
jacket.  It is attached to a peristaltic pump that allows the constant flow of solution.  
Cannulation occurs in the aorta for retrograde perfusion of the ascending aorta. This 
forces the aortic valve closed and shunts the blood flow via the coronary ostia into to the 
coronary arteries. Thus, the solution flowing through the Langendorff apparatus provides 
the nutrition and oxygen such that the ventricular myocardium is still functional.  For the 
first 3 to 5 minutes, the heart is perfused with BIS to wash out most of the blood.  The 
solution is then switched to enzyme solution to dissociate the cells (BIS plus 150 u/ml 
collagenase type II (Worthington)).  The perfusion with collagenase is continued until 
there is no blood left in the heart and it becomes white and boggy (typically 13 or 20 
minutes for mouse or rat respectively).  The heart is then removed from the Langendorff 
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apparatus and placed in a dish containing enzyme solution.  The rest of the steps are 
performed in a sterile hood. The heart is minced into small chunks and triturated using a 
sterile disposable pipette.  The solution of cardiac tissue is placed in a conical tube and 
allowed to sit at 37 °C for two minutes.  The solution is then filtered through 190 μm 
nylon mesh (Amazon.com) to remove any undigested tissue and centrifuged at 300 G 
for 2 minutes to pellet the ventricular cardiomyocytes.  The cells are then washed 
sequentially with increasing amounts of Ca2+ (50 μM, 250 μM, 500 μM, and 1 mM) in BIS 
plus 500 mg/ml bovine serum albumin (BSA solution) to quench the excess enzyme and 
perform Ca2+ tolerance. Between each Ca2+ step, the cells are allowed to pellet by 
gravity and the supernatant switched to remove dead cells and any bacteria that might 
have come from the initial isolation.  Following the final step of Ca2+ tolerance, the cells 
are resuspended in plating medium (Table 2) and plated onto sterile glass coverslips 
previously coated with 20 μg/ml laminin (Sigma) in Dulbecco’s Modified Eagles Medium 
in 24 well cell culture plates. The cells are then allowed to adhere for one hour.  
Following adherence, the cells are washed once with culture medium (Table 3), and 
culture medium plus or minus virus is added to the wells for 48 to 60 hour culture.   
The culture medium has some components that are worth describing further.  
Most importantly, it contains two contractile inhibitors: 2,3-butanedione monoxime (BDM) 
and blebbistatin.    BDM (Sigma) is a reversible myosin ATPase inhibitor that also has 
phosphatase-like properties (part of the oxime family).  For that reason, high 
concentrations were originally used to rescue cholinesterase activity lost due to 
organophosphate insecticide poisoning.122  It has been shown to be cardioprotective 
during ischemia and perfusion.123 We use it during isolation and in the culture medium to 
prevent the cells from contracting down and to reduce myocardial perfusion damage.124  
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While the potential effects on ion channel activity due to its phosphatase properties are 
less clear, it is known that lower concentrations of BDM (5 to 10 mM) do not have very 
high phosphatase activity and that BDM washes out within 5 minutes.124 Therefore 
during our electrophysiologic recordings, we do not include it in the bath solution, but 
ensure that the coverslip perfuses for 5 minutes with BDM-free solution prior to 
beginning recording. 
Blebbistatin (Toronto Research Chemicals) is a cell motility inhibitor that 
preferentially binds the ADP-Pi complex of myosin II, inhibiting myosin cycling.
125  It has 
been shown to extend the life of cultured adult ventricular cardiomyocytes and improve 
adenoviral gene transfer. Additionally, it has been used in a whole heart Langendorff set-
up to remove motion artifact such that imaging can be performed. 126, 127  I also use 
blebbistatin at 7.5 μM in my recording solution for performing whole-cell patch clamp. 
 
Figure 13: A, Langendorff aparatus schematic depicting the solution being 
sent through the peristaltic pump and into the water jacket for perfusion of the 
heart. B, comparison of freshly isolated cardiomycoytes and cultured 
cardiomyocytes.  DIV, days in vitro. Scale bar 20 μm. 
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Table 1: Basal Isolation Solution for Cardiomyocyte preparation 
  
FW 
Concentration  
(mM) 
Mass (g) for  
1 L 
NaCl 58.44 112 6.55 
KCl 74.56 5.4 0.40 
NaH2PO4·H2O 137.99 1.7 0.23 
MgCl2·6H2O 203.30 1.63 0.33 
NaHCO3 84.01 4.2 0.35 
HEPES 238.30 20.04 4.78 
D-Glucose 180.16 5.4 0.97 
Taurine 125.15 10 1.25 
L-glutamine 146.15 4.1 0.60 
L-carnitine HCl 197.66 2 0.40 
Creatine, anhydrous 131.13 2.3 0.30 
2’3-butanedione monoxime 101.10 10 1.01 
*pH to 7.2 with NaOH 
*check osmolarity (~ 300 mOsm/L) 
*filter sterilize 
*store at 4 °C 
 
Table 2: Plating Medium 
MEM with Earle's salts and L-glutamine (Mediatech)   
Penicillin-Streptomycin 100 u/ml 
Fetal bovine serum 5% 
2,3-butanedione monoxime 10 mM 
 
 42 
Table 3: Culture Medium 
MEM with Earle's salts and L-glutamine (Mediatech)   
Penicillin-Streptomycin  100 u/ml 
Bovine serum albumin 0.1 mg/ml 
2,3-butanedione monoxime 10 mM 
Insulin 10 μg/ml 
Transferrin 5.5 μg/ml 
Selenium 6.7 ng/ml 
Creatine, anhydrous 5 mM 
Taurine 5 mM 
L-carnitine HCl 2 mM 
Blebbistatin 25 μM 
 
2.3 Adenoviral transduction 
2.3.1 Introduction1 
The major impediment to performing physiologic studies in adult ventricular 
cardiomyocytes is that they cannot be efficiently transfected by methods typically used 
with immortalized cell lines. Adult ventricular cardiomyocytes are terminally differentiated 
cells and do not divide, so liposomal or chemical strategies for transfection are 
ineffective.  
Most investigators have therefore used viral vector-mediated gene transfer. 
Adenovirus was used first in the 1990s and proved to be very efficient in rat, rabbit,128 
                                               
1
 We were invited by Paul Insel, Editor-in-Chief for American Journal of Physiology-Cell Physiology to write 
an Editorial Focus to review methods of gene transfer in adult ventricular cardiomyocytes.  These 
paragraphs are largely based on this review article.  
 
Amenta JJ, Pitt GS. The glitter of gold: Biolistic transfection of fresh adult cardiac myocytes. Focus on 
"normal targeting of a tagged kv1.5 channel acutely transfected into fresh adult cardiac myocytes by a 
biolistic method". Am J Physiol Cell Physiol. 2010;298:C1305-1307 
 
The American Journal of Physiology-Cell Physiology, does not require permission to reprint in a dissertation. 
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and mouse129 adult ventricular myocytes. Although there is question as to whether 
adenoviral-mediated gene transfer disrupts cellular physiology by promoting 
dedifferentiation,130 this technique has enjoyed substantial success. For example, Zhou 
et al.129 were able to express either β1- or β2-adrenergic receptors and rescue 
contractile and calcium current responses to β-adrenergic receptor stimulation in β1/β2-
receptor double-knockouts, providing a means to study the effects of β-adrenergic 
signaling on Ca2+ currents in the ventricular cardiomyocyte. Lentivirus has also been 
used effectively and offers the advantage of having about two-fold greater transgene 
capacity relative to that of adenoviruses.131 A shortcoming, however, is very low 
transduction efficiency.  
2.3.1.1 Adenoviral gene transfer versus other modes in terminally differentiated 
cells 
Other methods of gene transfer in adult ventricular cardiomyocytes have been 
used successfully.  For example, Dou et. al.132 adapted the gene gun approach. This 
biolistic method, which uses high-speed propulsions of subcellular particles (typically 
gold) coated with DNA, has been successfully employed in neuronal tissue sections and 
primary neuronal culture systems, both of which share with ventricular myocytes the 
difficulty of transfection into terminally differentiated cells.133 Previous attempts to use 
this technique for ventricular myocytes failed to produce surviving, transfected 
myocytes—an experience that Dou et al. initially replicated. Systematic alterations to the 
standard protocol (e.g., omitting polyvinylpyrrolidone during preparation of the cartridges, 
and optimization of both gold particle size and bombardment pressure), however, 
yielded a transfection efficiency of almost 30% of surviving myocytes in less than 24 
hours, and the transfected cells remained viable and retained their morphological 
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characteristics. In cells transfected with labeled KV1.5, Dou et al. confirmed the 
localization of these channels at intercalated disks and demonstrated an increased, 
sustained K+ current component sensitive to 100 μM 4-aminopyridine, a KV1.5 blocker. 
While these results establish that KV1.5 channels are, indeed, localized to intercalated 
disks and, through use of expressed, truncated channels, identify channel determinants 
for proper trafficking to the plasma membrane, the most interesting result may be the 
demonstration of an effective and simple way to transfect genes into cardiac ventricular 
myocytes. 
Although transfection by gene gun may not be suitable for all applications, it 
offers significant advantages over viral transduction for certain experimental questions. 
For example, the opportunity to use plasmid DNA obviates the need for generating 
viruses, which should save considerable time and effort that could then be applied to 
experimental studies, such as more thorough and creative testing of multiple constructs 
and mutants. Moreover, the maintenance of the normal rod-shaped myocyte morphology 
after transfection suggests that information gained from gene gun transfections will 
provide valuable insights into the function of cardiac myocytes. 
Despite these bright spots, there are some areas in which this technique might 
lack luster. As reported by Dou et al., the gene gun bombardment method kills 90% of 
the viable myocytes, and of the 10% surviving, only ∼30% are transfected. Thus, this 
technique may be especially suited for single-cell experiments, e.g., imaging and 
electrophysiology as performed in this study, in which the ability to perform analysis in 
transfected myocytes transcends the need for highly efficient transfection; in contrast, 
the relatively low level of transfection will render biochemical analyses challenging. 
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I attempted the gene gun approach with a similar protocol as described by Dou 
et. al. however was unsuccessful.  Therefore, I utilized the adenovirus system,  which I 
will describe in more detail in the following section.  While it took more time and 
preparation to make the adenovirus, it ultimately provided the capability to perform both 
biochemical and single cell experiments in the same culture, with greater cell viability 
and reproducibility than reported by Dou et. al. with the biolistic approach.  
2.3.2 Materials and Methods 
We wanted to study the effects of knockdown of endogenous FGF13 on voltage-
gated Na+ channel function and targeting to the cell surface.  A shRNA to FGF13 and 
scrambled shRNA was designed by Chuan Wang (see Table 4 for sequence) with the 
RNA polymerase III H1 promoter.134 The FGF13 shRNA and scrambled shRNA was 
cloned into the pAdTrack-GFP plasmid obtained from ATCC using Sal I and Xho I 
restriction sites.  The rest of the procedure was performed as stated in Luo et. al.135 
Table 4: shRNA sequences cloned into pAdTrack 
FGF13  5’-GCACTTACACTCTGTTTAATTCAAGAGATTAAACAGAGTGTAAGTGC-3’ 
Scrambled 5’-GACCCTTAGTTTATACCTATTCAAGAGATAGGTATAAACTAAGGGTC-3’ 
 
To test the efficiency of knockdown, three strategies were employed.  The first 
was immunocytochemistry.  Because the virus expressed a GFP simultaneously with the 
shRNA, we could identify infected cells and stain them using an antibody specific to 
FGF13 (Figure 13A).78 We observed a large decrease in the immunoreactivity of the 
FGF13 antibody with FGF13 KD (Figure 14A).   
 46 
 
Figure 14: Specific knockdown of FGF13 by shRNA decreases Na+ channel 
current in adult mouse ventricular myocytes. (A) Confocal images of 
immunocytochemistry of FGF13 (red) after infection with adenovirus expressing 
FGF13 shRNA (bottom panels) or a Scrambled control (top panels) in ventricular 
myocytes. Infected myocytes were identified by GFP expression. Nuclei are 
stained with DAPI. Scale bar, 25 μm. (B) Quantitative analysis of FGF13 (using 
primers in the FGF-like core designed to amplify all FGF13 isoforms; see Online 
Table I) and FGF12B mRNA levels by qPCR in uninfected cultured myocytes 
(Control) or those infected with scrambled shRNA (Scrambled) or FGF13 shRNA 
(shRNA). All data were corrected with GAPDH and normalized to Control. **p<0.01, 
compare to control; n=6 for FGF13 and n=3 for FGF12-B. (C) Representative 
immunoblot of FGF13 protein expression in isolated control myocytes, or 
myocytes infected with Scrambled or shRNA. Result is representative of three 
independent experiments. (D) Histograms showing normalized amounts of FGF13 
protein from Control, Scrambled, or shRNA treated myocytes. **p<0.01, compared 
to control; n=3. GAPDH was used as loading control. Reprinted with permission 
from Wolters Kluwer, Circ Res, Wang C, Hennessey JA, Kirkton RD, Wang C, 
Graham V, Puranam RS, Rosenberg PB, Bursac N, Pitt GS. Fibroblast growth 
factor homologous factor 13 regulates Na+ channels and conduction velocity in 
murine hearts. Sep 16;109(7):775-82, copyright 2011. 
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Then, because of the high efficiency of adenoviral infection, we could perform 
more quantitative biochemical studies on the efficiency of our shRNA.  In Figure 14B, 
summarized data from quantitative reverse-transcriptase polymerase chain reaction 
shows about 90% knockdown of the total FGF13 transcripts.  Additionally, western blot 
using the previously described antibody to FGF13 showed similar results (Figure 14C-
D).78   
Additionally, I devised strategies to rescue the loss of FGF13 with a second 
adenovirus encoding a shRNA-resistant human FGF13 splice variant.  This is described 
in Chapter 3. 
Adenovirus was made using the commercially available AdEasy System (Agilent 
Technologies) designed by Bert Vogelstein’s lab.135  The shuttle vector pAdTrack-GFP 
was used to insert the shRNA and pAdRFP for the overexpression constructs described 
in Chapter 3.   
The adenovirus was purified using the VivaPure Adenopack 20 purification kit 
with some modifications to the protocol.  After at least two rounds of initial amplification 
in HEK293 cells, adenovirus was amplified in low-passage HEK293 cells in three to four 
T-75 flasks (about 40 mls). Once almost 100% of cells were fluorescing (ideally 5 days, 
but could be longer), cells were detached with a scraper (no trypsin) and put in conical 
tube. Cells were centrifuge at 3500 g for 15 minutes to pellet cell debris and all but 5 ml 
of supernatant is removed.  Cells were put through at least three freeze-thaw cycles 
(vortex, freeze in liquid nitrogen, thaw in 37 °C water bath) to lyse the cells and 
dissociate the majority of the virus which is stuck to the outside of the cells. The 
solutions from the three to four flasks are then combined and filtered through 0.45 μm 
cellulose acetate vacuum filters (Corning).  Benzonase (from the kit) is then added at 
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1:1000 dilution and solution incubated for 30 minutes at 37 °C in order to digest cellular 
nucleic acids.  The AdenoPACK 20 Maxi (clear top) is then equilibrated with 5 ml Wash 
Buffer and spun for 5 minutes at 500 g.  Use a swing out rotor centrifuge for the rest of 
the steps.  Digested supernatant is then loaded onto the Vivaclear Maxi (yellow top) and 
spun for 5 minutes at 500 g at 4°C or until whole volume passes through.  Flow through 
is collected and 10x loading buffer is added while vortexing the solution at low speed. 
Sample is then loaded onto the AdenoPack Maxi (clear top) and spun for 5 minutes at 
500 g or until whole volume has passed through the membrane.  The column is then 
washed twice with 18 ml washing buffer and virus eluted with 1 ml of elution buffer. 
Elution buffer is pipetted onto column membrane and incubated for 20 minutes at 4 °C.  
The column is then spun for 5 minutes at 500 g to elute.  This is repeated once to result 
in a total of 2 ml of eluate.  Eluate is transferred to a Vivaspin 20 centrifugal concentrator 
and virus storage buffer (20 mM Tris HCl pH 8.0, 25 mM NaCl, 2.5% Glycerol in ddH2O, 
filtered) is added to bring the volume to 10 ml. The concentrator is then spun for 30 
minutes at 800 g or until the volume has gone below 1 ml.  This is repeated again.  
Typically a volume of 700 μl produces 109 to 1011 optical density units/ml using the 
A260/280 nm measurement on the Nanodrop (Thermo).  Virus is then aliquoted and 
stored at 20 μl aliquots with 5 μl of virus added per well of a 24-well plate for 70% to 
100% infection efficiency.    
2.4 Electrophysiology 
2.4.1 Introduction 
With a method to isolate adult ventricular cardiomyocytes and effectively 
manipulate the levels of FGF13 in the cell, the next step is to test the effects of FGF13 
on Ca2+ and Na+ currents.   I performed whole-cell patch clamp and using a combination 
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of voltage changes and pharmacology, effectively isolated the individual Ca2+ and Na+ 
currents (ICa or INa, measured in amperes, A).  I went to Cold Spring Harbor Laboratory in 
2011 for the “Ion Channel Physiology” course.  It was there that I learned the true 
intricacies of patch clamping. In this section, I will summarize the method of patch clamp, 
and the pharmacology and voltage-parameters used in the experiments that follow. 
 Before the specifics, it is important to understand what parameters are being 
controlled and which recorded.  There are two modes of whole-cell patch clamp: voltage 
clamp and current clamp.  Voltage-clamp is a true “clamp,” during which you hold 
(clamp) the voltage at a specific level and record ionic currents activated at that specific 
voltage.  In contrast, current clamp does not actually clamp anything.  During current 
clamp, the cell is at its own resting membrane potential, typically -85 mV for ventricular 
cardiomyocytes.  The experimenter then injects depolarizing current beyond action 
potential threshold of the cell.  This induces the cell, through activation of voltage-gated 
Na+ channels, to fire an action potential which is recorded as the changing voltage.  In 
summary, current-clamp measures voltage changes and voltage-clamp is used to record 
ionic currents in response to a voltage step.  Typically, voltage clamp is used to isolate a 
single type of current (Ca2+ or Na+ for example) and record its biophysical properties.   
There are essentially four methods of recording ionic currents.  They all begin 
with the fabrication of a pipette with a microscopic tip, filling the tip with solution, of which 
we will discuss the components later in this section, attaching the pipette to a head stage 
attached to a micromanipulator, and immersing the tip in the bath solution.  The pipette 
is then pressed onto the cell to form a gigaseal (a high resistance, GΩ, seal).  The 
voltage in the pipette is then hyperpolarized and the capacitance derived from the 
pipette is cancelled.  It is after this step that the methods diverge (see Figure 15).136   
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2.4.2 Types of electrophysiologic recordings  
In cell-attached recording (Figure 15A) the pipette solution acts as the 
extracellular solution and the cytoplasm maintains its native state.  It is useful when 
unknown cytosolic factors are required for gating, or to see if its activity is changed in 
response to a second messenger.  One can add a ligand to the bath solution that the ion 
channel in question will be isolated from due to the pipette.  Therefore, if a change in 
activity is seen, it is likely due to a second messenger.  The disadvantages of this 
technique are the lack of ability to measure the resting membrane potential and no 
control over the intracellular cytosolic composition. 
From the cell-attached configuration, one can pull the pipette away from the cell 
and form an inside-out configuration (Figure 15B).  Because the inside of the cell is now 
immersed in the bath, this configuration allows one to change out the cytosolic solution 
to study cytosolic signals or enzymatic activities.  However, one disadvantage is the 
complete loss of the endogenous cytosolic factors that control channel behavior. 
From the cell-attached configuration as well, applying negative pressure leads to 
rupture of the membrane and movement into whole-cell configuration (Figure 15C).  In 
whole-cell configuration, one records an average of all of the ion channels within the cell.  
Here, the experimenter controls the extracellular (bath) and the intracellular (pipette) 
solution, and thus can optimize conditions for the current of interest.  However, there is 
loss of endogenous cytosolic factors because the pipette solution dilutes all of them out 
and it is impractical to change the pipette solution during a given recording.   
Finally, in the whole-cell configuration, one can pull the pipette away to form an 
outside-out patch (Figure 15D).  This allows rapid exchange of solutions on the 
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extracellular side and useful for recording ligand-gated ion channels.  Again, the major 
disadvantage is the loss of the cytosolic environment.   
In cell-attached, inside-out, and outside-out recording methods, one records 
single channel activity. This provides data on biophysical characteristics of the channel 
such as conductance, voltage-dependence, selectivity, and open probability.  Whole-cell 
recording reveals the role of these channels in the context of whole-cell physiology.  For 
my studies, I used whole-cell patch clamp on ventricular cardiomyocytes (Figure 15D) to 
explore the role of Ca2+ and Na+ channels in cardiomyocyte physiology. 
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Figure 15: Different modes of patch clamping A, cell-attached patch. B, 
inside-out patch. C, whole-cell patch. D, outside-out patch. E, brightfield image of 
a ventricular cardiomyocyte with a patch pipette sealed, just prior to going into 
whole-cell configuration.  Scale bar 20 um. 
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2.4.3 A closer look into whole-cell patch clamp 
2.4.3.1 The cell as a simple circuit 
The simplest way to understand the measurements taken in whole-cell patch 
clamp is to envision the cell as a circuit (Figure16A).   
 
Figure 16: The cell as a simple circuit.  A, The cell has membrane 
resistance (RM), a voltage gradient (ER), and capacitance, C.  The pipette gives a 
test potential, VP, which drops over the series resistance of the pipette, RS, such 
that the cell sees test potential, V. B, example of a test potential given through the 
pipette and the response of the cell, C. Iin, instantaneous current; ISS, steady-state 
current. Modified from Sakman and Neher, 2009.136 Permission not required from 
Springer Science and Business media if it is a “small excerpt for…scholarly 
analysis.” 
The plasma membrane is a capacitor, defined as a narrow gap between two 
conductors.  This creates a separation of charge in which the cell is more negative on 
the inside compared to the outside.  Capacitance (C) is defined by how much charge (Q) 
needs to be transferred between the two conductors to set up a potential (V) difference 
between them. 
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Equation 2: Definition of capacitance 
 
Capacitance is measure in Farads (F).  Cell membranes act as capacitors with a specific 
capacitance of 1.0 μF/cm2.  Capacitance is directly proportional to the area of the cell 
and dielectric constant, and inversely proportional to the distance between the 
conductors.  As the membrane bilayer is quite thin only about 2.3 nm, and the dielectric 
constant of hydrocarbons is 2.1, cells have a high electrical capacitance due to their 
molecular dimensions. This results in a small amount of charge having a large effect on 
membrane potential.4 
 As an example, we have gone into whole-cell configuration on a cell that is 
relatively small (~50 pF), and that is healthy and therefore has a high membrane 
resistance (RM) of greater than 1 GΩ.  The patch pipette has a series resistance (Rs).  
Note that it is named series resistance because in this circuit, there are two resistors in 
series, first the pipette, then the ion channel.  In voltage clamp (Figure 16B), the cell is 
held at a hyperpolarized potential compared to the bath (ground electrode) and given a 
square pulse of amplitude ΔV, the current (Figure 16C) is measured as a single 
exponential, where V0 is the original voltage, time is t as shown in Equation 3, 
Equation 3: Discharge of an RC circuit 
 
 It is assumed that RM >> RS (typically 1 GΩ and 1-10 MΩ, respectively), three 
equations are obtained: 
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Equation 4: Instantaneous current 
 
Equation 5: Steady-state current 
 
Equation 6: Tau 
 
 Iin is the first jump of current just after the change in voltage and ISS is the steady 
state current.  τ is the time constant of the relaxation of the current, measured by fitting a 
single exponential equation to decay the decay from Iin to Iss. 
Equation 7: Single exponential function to calculate τ 
 
Then, using Equations 4, 5 and 6, RM, C, and RS can be calculated.  C and RS are 
particularly important measurements.  The specific capacitance of a cell is 1.0 μF/cm2.  
Thus the capacitance of the cell is directly proportional to the size of the membrane and 
therefore the size of the cell.  We use this measurement to normalize the amount of 
current recorded such that we can compare among cells of different sizes, resulting in a 
measurement of current density (pA/pF).  C is calculated from Equation 6. Rs is inversely 
proportional to how well the membrane has been ruptured.  A full rupture of the 
membrane within the pipette will give a low Rs of about one to three times the pipette 
capacitance, thus giving a larger (and more accurate) calculation of cell capacitance.  If 
Rs is high due to incomplete rupture or debris in the pipette, C can be artificially 
calculated as smaller than what would be measured, thus artificially increasing the 
calculation of current density. 
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 Additionally, recall that RS is series resistance because there are two resistors in 
series with each other (Figure 16A), therefore the two resistances summate, leading to 
two voltage drops.  This leads to a discrepancy between the pipette potential, VP, and 
the cell potential, V. In the case of voltage-clamp, we want to measure the current in 
response to a specific voltage, and therefore this discrepancy would lead to the cell 
responding to a smaller voltage.  Additionally, the high series resistance can lead to the 
cell firing an action potential upon a voltage step because it takes to long for the voltage 
to reach its max.  This means the cell is no longer clamped at the VP, leading to a 
complete loss of voltage control.   Capacitance is also compensated such that no net 
current is recorded by the amplifier due to charging of the capacitor.  This does not 
change the time course of V. 
2.4.3.2 Voltage-clamp protocols 
2.4.3.2.1 Introduction 
Once the cell has been ruptured and proper compensation complete, it is time to 
switch to a recording solution specific to the channel of interest and run the protocols 
that elicit those currents.  
2.4.3.2.2 Solutions 
The proper composition of solutions is critical for ensuring the current of interest 
is being isolated.  In this section, I will focus on the solutions used to record Ca2+ 
currents as an example but these same principles apply for most currents of interest. It is 
useful to first look at the ionic content of a typical cell (Table 5), then decide which 
components need to be changed. The final solutions used in the experiments can be 
found in Section 3.3.3.
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Table 5: Free ion concentrations and equilibrium potentials 
Ion Extracellular 
concentration (mM) 
Intracellular 
concentration (mM) i
O
Ion
Ion
][
][
 
Equilibrium 
potential (mV)* 
Na+  145 12 12 +67 
K+  4 155 0.026 -98 
Ca2+  1.5 100 nM 15,000 +129 
Cl- 123 4.2 29 -90 
From Hille, 2001.4     
*Calculated from Equation 1. 
           We will start with the intracellular solution.  K+ is the most abundant ion inside the 
cell at 155 mM.  K+ has a reversal potential of -98, thus any depolarizing steps will lead 
to an outward current.  This outward current will contaminate (and potentially mask 
entirely) our inward Ca2+ current, therefore we need to replace K+ with another 
monovalent cation.  We choose Cs+ for this purpose because it blocks K+ channels while 
giving us equal osmolality to K+.  Most solutions contain CsCl, Cesium aspartate, and/or 
CsF.  The salt provides balanced charge.  Additionally, for cardiomyocyte recordings, we 
remove the Ca2+ from the solution completely because if not buffered down to the typical 
intracellular levels it will cause cell contraction and a loss of the seal.  Mg2+ replaces 
Ca2+ and anecdotally makes it easier to seal on to the cell. Na+ is important for the 
Na+/K+ ATPase and NCX function therefore we will keep a similar amount of Na+ to the 
typical cell.  Finally, Cl- is the anion to counter all the cations we’ve added and stays 
about the same.  The next component, HEPES is a buffer that keeps the solution at the 
physiologic pH of 7.2 to 7.3.  HEPES is a “Good’s Buffer,” which maintains pH despite 
changes in carbon dioxide concentration produced by cell respiration better than 
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bicarbonate buffers.137 Ethylene glycol tetraacetic acid (EGTA) is a divalent cation 
chelator that has a much higher affinity for Ca2+ than Mg2+.  This is required to maintain 
low free Ca2+ even when we’re recording Ca2+ currents to keep the Ca2+ from binding to 
the sarcomeres and leading to contraction.  Finally, the cell needs energy to allow the 
channels to open and close in response to voltage.  Energy is provided as GTP, ATP 
and phosphocreatine.  Once a solution is made and brought to the goal pH with the 
proper acid or base (in this case CsOH), the osmolality should be calculated and also 
checked using a vapor pressure osmometer.  While we are changing the components, 
we don’t want to change the overall osmolality of the cell which could lead to changes in 
osmotic pressure. 
 Turning to the external solution, we need to think of which ions we want to allow 
through the channels when we depolarize the cell and which we want to block.  We are 
recording Ca2+, an inward current.  Therefore, we do not want any Na+ currents to 
contaminate our results.  To do this, we get rid of all Na+ in the extracellular solution.  
We replace the Na+ with two components.  The first is Cs+, which was discussed 
previously.  It is a monovalent cation that blocks K+ channels.  Additionally, N-methyl-D-
glucamine (NMDG) is a membrane impermeable, monovalent cation that also blocks K+ 
channels (again so that the outward K+ current does not mask our inward Ca2+ current). 
NMDG and Cs+ are quite good at blocking the slow K+ channels, but do a poor job 
blocking the fast, A-type current carried by the KV4 channels and responsible for Ito in the 
ventricular cardiomyocyte.  To account for these currents, 4-aminopyridine is added to 
the extracellular solution, which acts as a specific blocker of A-type K+ currents.  Again, 
HEPES is present as a pH buffer and glucose provides energy for the cell.  Ca2+ is 
 59 
necessary to record Ca2+ currents, although Ba2+ can also be used as a charge carrier.  
Mg2+ balances the osmolality and aids with sealing onto the cell with the patch pipette. 
2.4.3.2.3 Voltage protocols 
Now that the cell is sealed, compensation is complete and we have detailed the 
components of the solutions required to record currents, the final step is to give a 
voltage-protocol and record the currents elicited.  Again, I will use Ca2+ currents as an 
example.  The protocols for Na+ currents are generally the same with the exception of 
timing (because Na+ channels have a much faster activation and inactivation time). The 
analysis is the same for both.  In whole-cell recordings, there are three basic 
measurements that are taken: Current density, voltage-dependence of activation, and 
steady-state inactivation.  To get these three measurements, two protocols need to be 
run. 
The first is a basic voltage step protocol.  In this case, the cell is being held at a 
hyperpolarized potential (typically -80 mV for cardiomyocytes) and stepped to 
depolarizing voltages (Figure 17A) and an inward current is recorded (Figure 17B).  The 
peak current for each voltage-step is recorded and plotted as the current (I, y-axis) 
versus voltage (V, x-axis) to give a typical I-V plot (Figure 17C).  As stated earlier, this 
current is normalized to the cell size, measured as capacitance to give a current density 
measurement (pA/pF), so comparisons can be made between cells, although it is just 
shown as current in Figure 17C.  Additionally, the voltage-dependence of activation, a 
measure of channel availability is calculated from a voltage-step protocol.  While the I-V 
plot peaks at -10 mV in the example in Figure 17C and then starts decreasing, the 
channel is remaining open.  However, the driving force for Ca2+ is beginning to reverse.  
Such a depolarized voltage results in a smaller driving force for Ca2+, a cation to go 
through the channel.  Therefore, although it appears that some channels have started to 
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close, the channels are still open, but there is less driving force for Ca2+ to move inside 
the cell. To analyze the availability of the channel as a result of voltage, we express the 
current in terms of conductance (g) according to Equation 8. 
Equation 8: Conductance equation 
 
Where VCa is the reversal potential of for ICa and V is the potential of the voltage pulse.  
V-VCa is the net driving force on the Ca
2+ ions.  We can calculate the reversal potential 
from our solutions using Equation 1, the Nernst equation, we record the ICa, and 
therefore the variable left is g.  We take this data and normalize it to its maximum 
(G/GMax) to show what fraction of the total conductance is available at a given voltage.  
This data is then fit with a Boltzmann function, 
Equation 9: Boltzmann 
 
where VM is the membrane potential, and the V1/2, the voltage in which half the channels 
are activated, and the slope, k, of the function are calculated (Figure 17D). 
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Figure 17: Typical  recording and analysis of a voltage-step protocol. A, 
example of the voltage-steps given.  Each step has six seconds in between to 
allow full recovery of the channel.  B, recording of Ca2+ current in response to the 
voltage protocol in A.  C, the Ca2+ current data directly derived from the protocol 
in A is the current-voltage (I-V)relationship.  Using Equation 8, the I-V curve is 
converted into a sigmoidal activation plot from which we can derive the V1/2 and k. 
The second protocol provides data on steady-state inactivation, or the voltage-
dependence of inactivation.  In this protocol, the cell is held at a given test potential for 1 
s (P1), and then given a pulse that activates its peak current (P2, for Ca2+ the step is to   
-10 mV or 0 mV).  This is illustrated in Figure 18A. The basic idea is that a certain 
percentage of the channels will become inactivated during P1, then the rest that are still 
available will be elucidated during P2.  The first potentials of P1 are at more 
hyperpolarized potentials compared to the activation of the channel and thus during P2, 
maximum current is obtained (Figure 18B).  Take for example, at P1 = -50 mV (magenta 
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in Figure 18).  During P1, there is no current recorded, and during P2, there is the 
maximal current.  Then look at -10 mV for P1 (maroon).  Maximal current is obtained 
during P1 and therefore little to no current is obtained at P2.  The P2 current (I) 
normalized to the maximum P2 current (IMax) is plotted against the test potential in P1 to 
create a steady-state inactivation curve (Figure 18C).  This is fitted to a Boltzmann 
equation, 
Equation 10: Steady-state inactivation 
 
such that the V1/2 and k can be obtained (Figure 18C).   
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Figure 18: Typical two-step protocol with recording and analysis of channel 
steady-state inactivation.  A, two-pulse protocol, and recording, B.  Pulse 1 (P1) is 
stepped to different voltages and the relative current available during pulse 2 (P2) 
is plotted against the P1 voltage, C.  This is fit with a sigmoidal function to derive 
V1/2 and k.  
When plotted together, the voltage-dependence of activation and the steady-
state inactivation graphs demonstrate the window of voltage in which the channel is 
activated, but not inactivated yet (Figure 19), a measure of channel availability.  Any shift 
in the activation or inactivation curves can change the size of that window, increasing or 
decreasing the availability of the channel at a given voltage.  
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Figure 19: The voltage-dependence of activation and steady-state inactivation 
curves plotted on the same graph to show the availability window of the channel, 
so called the window current (red striped region).  This occurs at voltages which 
the channel is activated, but not inactivated. 
 
2.4.4 Conclusion 
While complex, electrophysiologic recordings provide a live, in vivo picture of the 
activity of ion channels within the cell.  Using these methods in the following chapters, I 
will elucidate the roles of a modulator protein family, fibroblast growth factor homologous 
factors, in regulating voltage-gated Na+ and Ca2+ currents.  
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3. Fibroblast growth factor homologous factors 
modulate cardiac calcium channels 
 
This chapter is based on a manuscript accepted to Circulation Research. 
 
Reprinted with permission from Wolters Kluwer, Circ Res, Hennessey JA, Wei EQ, Pitt 
GS. Fibroblast growth factor homologous factors modulate cardiac calcium channels, 
[Epub ahead of print] June 26. copyright 2013. 
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3.1 Summary 
Fibroblast growth factor (FGF) homologous factors (FHFs, FGF11-14) are 
intracellular modulators of voltage-gated Na+ channels, but their cellular distribution in 
cardiomyocytes indicated that they performed other functions.  Therefore, we aimed to 
uncover novel roles for FHFs in cardiomyocytes starting with a proteomic approach to 
identify novel interacting proteins. Affinity purification of FGF13 from rodent ventricular 
lysates followed by mass spectroscopy revealed an interaction with Junctophilin-2, a 
protein that organizes the close apposition of the L-type Ca2+ channel, CaV1.2, and the 
ryanodine receptor, RyR2, in the dyad. Immunocytochemical analysis revealed overall T-
tubule structure and localization RyR2 were unaffected by FGF13 knockdown in adult 
ventricular cardiomyocytes, but localization of CaV1.2 was affected. FGF13 knockdown 
decreased CaV1.2 current density, and reduced the amount of CaV1.2 at the surface due 
to aberrant localization of the channels. CaV1.2 current density and channel localization 
were rescued by expression of a shRNA-insensitive FGF13, indicating a specific role for 
FGF13. Consistent with these newly discovered effects on CaV1.2, we demonstrated 
that FGF13 also regulated Ca2+-induced Ca2+ release, indicated by a smaller Ca2+ 
transient after FGF13 knockdown. Further, FGF13 knockdown caused a profound 
decrease in the cardiac action potential half width. This study demonstrates that FHFs 
are not only potent modulators voltage-gated Na+ channels, but also affect Ca2+ 
channels and their function. We predict that FHF loss-of-function mutations would 
adversely affect currents through both Na+ and Ca2+ channels, suggesting that FHFs 
may be arrhythmogenic loci, leading to arrhythmias through a novel, dual-ion channel 
mechanism. 
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3.2 Introduction 
Despite an ever-growing understanding of ion channel structure, function, and 
regulation, many components of the macromolecular complexes anchored by ion 
channels are not yet known or well characterized. Identification of these channel 
interacting proteins and discovery of their functions within the channelsome provides 
important insight into physiologic and pathologic function. Mutations in newly defined 
channel interacting proteins often explain genetic causes of arrhythmias in cases where 
mutations in known arrhythmia loci are not found. Fibroblast growth factor (FGF) 
homologous factors (FHFs), a subfamily of FGF proteins (FGF11-FGF14) expressed 
predominantly in excitable cells,76 are prime examples of channel interacting proteins for 
which cardiac functions are not well understood.  Although part of the FGF superfamily, 
FHFs do not function as growth factors and are incapable of activating FGF receptors.138 
Rather, FHFs remain intracellular and have been shown to bind and modulate voltage-
gated Na+ channels.80, 139 Their roles as Na+ channel regulators have been studied most 
extensively in the brain, driven in large part by the identification of FGF14 as the locus 
for spinocerebellar ataxia and by observations that Fgf14-/- mice display an ataxia 
phenotype that correlates with decreased Na+ channel function and diminished neuronal 
excitability.140, 141  
FHFs are also expressed in cardiomyocytes, but their roles in regulating cardiac 
function have heretofore received less attention. We showed that FGF13, the most 
highly expressed FHF in murine heart, directly binds NaV1.5, the predominant cardiac 
Na+ channel, and participates in trafficking NaV1.5 to the sarcolemmal membrane and 
modulating Na+ channel kinetics.43, 78, 81  Consistent with these regulatory roles for Na+ 
channels, knockdown of FGF13 led to a reduction in conduction velocity and maximum 
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capture rate (the ability of the cells to recover from a stimulus of a specific speed) in a 
neonatal rat ventricular cardiomyocyte monolayer.78   
Several lines of evidence suggest that the effects of FHFs in excitable cells 
extend beyond Na+ channel modulation. For example, the complex changes in synaptic 
physiology in Fgf14-/- mice are not consistent with a defect limited to Na+ channel 
dysfunction.142 Indeed, we recently found that FGF14 knockdown in cerebellar granule 
cells reduced presynaptic Ca2+ currents and synaptic transmission at the granule cell to 
Purkinje cell synapse.143 Moreover, as we reported,78 the cellular distribution of FHFs in 
ventricular cardiomyocytes extended beyond the distribution of NaV1.5 channels. We 
therefore aimed to determine novel roles for FHFs in cardiomyocytes by looking for new 
FHF interactors. Here we report the discovery that that junctophilin-2 (JPH2) interacts 
with FGF13 in rodent ventricular myocytes. JPH2 is a protein responsible for 
coordinating the interaction of the sarcolemma and sarcoplasmic reticulum in the dyad. 
We therefore investigated the role for FGF13 in regulating ionic currents in the dyad and 
showed that FGF13 has essential roles in regulating the L-type, voltage-gated Ca2+ 
channel (CaV1.2) currents in adult ventricular myocytes. These results provide to the 
best of our knowledge the first evidence that FHFs modulate ion channels other than 
voltage-gated Na+ channels in cardiomyocytes and highlight previously unknown 
modulatory roles for FHFs in cardiac physiology, such as regulation of Ca2+-induced 
Ca2+ release (CICR) and the integrated electrical activity of the ventricular action 
potential. Our results lead to the hypothesis that loss-of-function mutations in FHFs 
could underlie inherited cardiac arrhythmias. 
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3.3 Materials and Methods 
3.3.1 Adenovirus 
The adenoviruses expressing FGF13 shRNA or scrambled shRNA with GFP has 
been previously described.78 FGF13 rescue viruses and the shRNA virus with the GFP 
removed were generated similarly using the AdEasy System (Agilent).  For rescue, 
human FGF13VY was mutated at the site of shRNA recognition to replace each third 
nucleotide (see Table _ for primers), changing the DNA sequence but not the ultimate 
protein product.  This construct was subcloned into pAdRFP (Addgene).  The adenoviral 
plasmid was packaged in HEK293 cells.  The recombinant virus was isolated by multiple 
freeze/thaw cycles, further amplified and then purified and concentrated using Vivapure 
Adenopack 20 (Sartorius Stedim Biotech).  The viral titer was determined using optical 
density.  All constructs were confirmed by sequencing.  
Table 6: Mutagenesis primers 
Forward 5' CACCAAAGATGAGGACAGTACCTATACCCTATTCAATCTCATCCCTGTGGGTCTG 3' 
Reverse 5' CAGACCCACAGGGATGAGATTGAATAGGGTATAGGTACTGTCCTCATCTTTGGTG 3' 
 
3.3.2 Cardiomyocyte isolation 
Animals were handled according to National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. The study was approved by Duke University 
Animal Care and Welfare Committee.  Cardiomyocytes were isolated from 6-8 week old 
C57/Bl6 mice or Sprague Dawley rats and cultured as previously described.78 Animals 
were anesthetized with Avertin and anti-coagulated with heparin.  Hearts were removed 
and the aorta was cannulated to perfuse the heart using a Langendorff apparatus.  The 
hearts were first perfused with basal solution containing (in mM, from Sigma unless 
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otherwise specified): NaCl 112, KCl 5.4, NaH2PO4H2O 1.7, NaHCO3 4.2, MgCl6H2O 
1.63, HEPES 20, glucose 5.4, taurine 30, L-carnitine 2, creatine 2.3, 2,3-butanedione 
monoxime (BDM) 10.  After five minutes, the solution was switched to basal solution plus 
150 u/ml Collagenase Type II (Worthington) and the heart was perfused until it was soft 
and boggy.  The heart was then taken down from the Langendorff, minced, and triturated 
in enzyme solution until all cell clumps were broken.  Calcium tolerance was performed 
in basal solution plus 5 mg/ml bovine serum albumin to quench the enzyme.  For culture, 
cells were plated on laminin coated coverslips or glass bottom plates (MatTek) in plating 
medium of Minimal Essential Medium (MEM) with Earle’s Salts and L-glutamine 
(Mediatech), 10 mM BDM, 5% fetal bovine serum (Life Technologies) and 1% 
penicillin/streptomycin (Sigma).  After cells had adhered to the plates, the cells were 
washed once and the medium changed to culture medium into which the proper 
adenovirus had been added.  Culture medium contained MEM with Earle’s Salts and L-
glutamine, bovine serum albumin 0.5 mg/ml, BDM 10 mM, 1X insulin-selenium-
transferrin supplement (Life Technologies), creatine 5 mM, taurine 5 mM, L-carnitine 2 
mM, and blebbisatin 25 µM (Toronto Reseach Chemicals).  All solutions were 
oxygenated in 95% O2/5% CO2 for at least 30 minutes.  Cells were then analyzed for 
electrophysiology, immunocytochemistry and Ca2+ transient recording 36-48 hours later.  
3.3.3 Electrophysiology 
Ca2+ currents (ICa) were recorded using the whole-cell patch-clamp technique as 
previously described.144 Voltage-clamp experiments were performed at room 
temperature (22-24 °C), 36-48 hours after infection of adult cardiomyocytes with 
adenovirus.  Bath (Tyrode) solution (Table 7) contained (in mM, from Sigma): NaCl 140, 
KCl 5.4, CaCl2 1, MgCl2 1, HEPES 5, glucose 10, pH 7.3 adjusted with NaOH.  Once the 
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cell was ruptured, solution was quickly changed to recording solution (Table 8) 
containing (in mM, from Sigma): N-Methyl-D-glucamine 150, HEPES 10, CsCl 2, CaCl2 
2, MgCl2 1.2, 4-aminopyridine 2, D-glucose 5.5, pH 7.3 adjusted with CsOH.  Internal 
solution (Table 9) contained (in mM, from Sigma): CsOH•H2O 70, aspartic acid 80, CsCl 
40, NaCl 10, HEPES 10, EGTA 10, MgATP 5, Na2GTP 0.2, Na2-phosphocreatine 5, pH 
7.3 adjusted with CsOH. Osmolarity was adjusted to ~300 mOsm with sucrose for all 
solutions.  Recordings were filtered at 5 kHz and digitally sampled at 25 kHz. Amplitude 
was normalized to cell capacitance (pA/pF).  Data analysis was performed using 
Clampfit 10.2 software (Axon Instruments) and Origin 8 (Originlab Corporation).  For 
current clamp, perforated patch with 400 nM amphotericin (Sigma) was performed using 
the following internal solution (Table 10)145 (in mM, from Sigma) KCl 110, NaCl 5, 
MgATP 5, Na2-phosphocreatine 5, Na2GTP 1, HEPES 10, pH 7.3 and Tyrode 
extracellular solution.  Cells were stimulated with current injections at 1 Hz at 1.5x 
threshold to induce action potentials recorded with 25 kHz sampling frequency.  Input 
resistance was not different between the groups and junction potential was calculated to 
be 5.6 mV and not corrected.   
3.3.4 Sarcoplasmic reticulum load measurements 
Cardiomyocytes were plated on glass bottom plates, cultured and infected with 
virus.  After two days in culture, cells were washed twice with Tyrode solution and 
loaded with 0.25 µM Fura-2 AM for 15 minutes.  Cells were then washed three times 
with Tyrode solution and allowed to de-esterify for 30 minutes.  Cells were field 
stimulated at 1 Hz with a 50 V unipolar pulse for at least one minute prior to recording to 
allow them to reach steady state.  Calcium transients were measured by excitation of 
Fura-2 with alternating 340 nm and 380 nm wavelengths of light (cycle time 4 ms) once 
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the cells had reached steady state.  After a 10 s pause, 10 mM caffeine was rapidly 
applied. Following recording, cells were moved out of the field of view and background 
fluorescence was measured for subtraction.  Background subtracted SR load peak 
height was measured using IonWizard software (IonOptix).   
3.3.5 Immunocytochemistry and T-tubule staining 
Immunocytochemistry methods have been previously described.78 
Imager/analyzer was blinded to the manipulation and all cells imaged were used for 
analysis. Cardiomyocytes on glass coverslips were washed in PBS and fixed for 15 
minutes in 2% paraformaldehyde in PBS.  Fixation was quenched with 10 mM glycine in 
PBS and cells were permeabilized with 0.2% triton X-100 in PBS for 8 minutes.  Non-
specific binding was blocked with 10% goat serum for one hour at room temperature.  
Cells were then incubated in primary antibody dissolved in antibody dilution solution 
containing 3% goat serum, 1% bovine serum albumin and 0.1% triton X-100 in PBS 
overnight at 4 °C. Primary antibody concentrations were anti-FGF13 1:400,78 anti-α1C 
1:1000 (Alomone), anti-RyR 1:1000 (Sigma), anti-NCX 1:1000 (generously provided by 
G. Vann Bennett, Duke University146). Cells were washed three times with PBS then 
incubated in secondary antibody in antibody dilution solution for 45 minutes at room 
temperature. Secondary antibodies were conjugated to Alexa-fluor 488, 633 (Life 
Technologies) or Cy3 (Jackson Immunoresearch). Following three more washes, 
coverslips were mounted in Vectashield (Vector Labs). For T-tubule staining, cells were 
plated onto glass bottom plates (MatTek Corp.) and cultured as above.  Cells were then 
washed twice with Tyrode solution and incubated in 0.5 µM di-8-ANEPPS (Life 
Technologies) in Tyrode solution plus 25 µm blebbistatin to inhibit contraction.  Cells 
were imaged live.  For all image analysis, control plates were imaged first. To ensure 
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there were no effects of culture on cells, only those cultures in which greater than 95% of 
the controls had proper α1C localization were used for analysis.  All images were 
collected on a Zeiss 510 inverted confocal microscope with a Zeiss 63x oil (NA, 1.4) or a 
Zeiss 40x oil (NA, 1.3) lens for immunocytochemistry or live imaging, respectively at 
room temperature.  The pinhole was set to 1.0 (Airy Disc) using Carl Zeiss Imaging 
software (version 4.0, SP1).  For CaV1.2, NCX and RyR localization, 0.5 µm stacks were 
taken at 512 x 512 resolution with 3x digital zoom.  For T-tubule staining, a single slice 
was imaged through the center of the cell.  All cells were prepared identically, and 
imaged by using identical parameters (e.g. gain, offset, magnification, brightness, 
contrast, pinhole, scan time, resolution, etc.).  
3.3.6 Image processing and Fast Fourier Transform 
The experimenter analyzing images was blinded to treatment. Stacks were 
deconvolved using Hyugens software (Scientific Volume Imaging) and exported as Tiff 
files.  Voxel colocalization was performed on deconvolved images using Pearson 
correlation coefficient.  For channel localization, images were imported into ImageJ 
(NIH), and 15 µm by 5 µm, non-nuclear, non-sarcolemmal sections were selected and 
line scanned to create an average plot profile as in Figure 3B.  The data was then 
imported into OriginLab software and a fast Fourier transform was performed at a 0.1 
µm-1 sampling frequency.  Peaks analyzed ranged from 1.8 µm to 2.1 µm intervals.  The 
amplitude at the peak was then compared between the groups.   
3.3.7 Simultaneous patch clamping and Ca2+ transient recording 
Cardiomyocytes were plated onto glass bottom plates (MatTek Corp.) and 
cultured as above.  Viruses expressing GFP were not used as GFP interferes with the 
Fura-2 emission. Therefore the cells were co-infected with a virus expressing mRFP to 
 74 
identify infected cells.    Cells were washed twice with Tyrode solution. Whole cell patch 
clamping was performed as above with the following modifications. Internal solution 
contained (in mM, from Sigma): CsOH•H2O 70, aspartic acid 80, CsCl 40, NaCl 10, 
HEPES 10, Fura-2 pentapotassium salt 0.150 (Life Technologies), MgATP 5, Na2GTP 
0.2, Na2-phosphocreatine 5, pH 7.3 adjusted with CsOH. Bath solution was a normal 
Tyrode solution.  Prior to rupture, emission was recorded to account for 
autofluorescence.  Upon rupture, cells were recorded at rest until a steady basal [Ca2+]i 
was recorded for at least 30 seconds.  Cells were then given a series of 50 ms voltage 
steps to 0 mV from holding at -40 mV (to inactivate Na+ channels) at 0.5 hz to equalize 
SR contents and then one 500 ms pulse to 0 mV that was used for measurement.  
Following recording, the patch pipette was removed and the cell moved out of the field to 
account for background fluorescence. Current was normalized to cell capacitance 
(pA/pF).  For Ca2+ transient peak measurement, background emissions were first 
subtracted and the peak was measured as the difference from the baseline using 
IonWizard software (IonOptix). EC-coupling gain was defined as the Ca2+ transient peak 
divided by the Ca2+ current peak. 
3.3.8 Immunoprecipitation 
Fresh adult mouse ventricular heart lysate was prepared by homogenizing tissue 
on ice in lysis buffer containing 150 mM NaCl, 50mM Tris, 1% Triton X, and protease 
inhibitor cocktail (Roche) as previously described.78  10 μg of anti-JPH2 (Santa Cruz), 
anti-FGF13, or anti-α1C antibody, or control IgG rabbit/goat (Santa Cruz) were used. 
Samples were subjected to SDS-PAGE and co-immunoprecipitation was verified by 
western blot. 
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3.3.9 Proteomics 
To crosslink anti-FGF13 antibody to agarose beads, 20 μg of FGF13 antibody or 
control rabbit IgG was coupled to 40 μl of protein A/G agarose beads in 1 ml PBS. After 
rocking overnight at 4 °C, beads were washed 3 times with 1 ml of 0.2M sodium borate 
(pH 9). Dimethyl pimelimidate (DMP) crosslinking reagent (Thermo Scientific) was 
dissolved in 0.2 M sodium borate (pH 9) to make 20mM DMP solution, and added to the 
coupled beads. After rocking at room temperature for 40 minutes, the sample was spun 
down and supernatant removed. The crosslinking reaction was quenched with 0.2M 
ethanolamine (pH 8) and the antibody cross-linked beads were ready for use.  
Ventricular tissue lysate (~23 mg total protein) was added to cross-linked beads, and 
rocked overnight at 4 °C.  Beads were washed 3 times with lysis buffer and eluted in 400 
μl of 0.2% Rapigest SF Surfactant (Waters) in 50 mM ammonium bicarbonate. Samples 
were heated at 70 °C for 10 min, centrifuged, and the supernatant was subjected to an 
in-solution tryptic digestion. Peptide identifications were determined by the Duke 
Proteomics Core Facility using liquid chromatography/tandem mass spectrometry; 
following data acquisition, all spectra were searched against the SwissProt database 
with the mouse taxonomy selected. 
3.3.10 Biotinylation and western blotting 
Surface biotinylation and western blotting were performed as previously 
described.78 Cardiomyocytes were plated on laminin coated 60 mm plates, infected with 
adenovirus and cultured.  After two days, cells were washed twice with cold PBS and 
incubated with 1 mg/ml EZ-Link Sulfo NHS-SS Biotinylation (Pierce) in cold PBS for 30 
minutes.  Biotinylation was quenched with 100 mM glycine in PBS and cells were lysed.  
Biotinylated proteins were incubated with NeutrAvidin (Pierce) overnight, then washed 
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three times and eluted in 2x LDS Sample Buffer (Life Technologies) plus 10 mM 
dithiothreiotol.  The biotinylated proteins and the whole lysate were run on 8-16% tris-
glycine SDS page gels, transferred to PVDF membrane and western blotted.  Primary 
antibodies used were anti-α1C 1:1000 (Alomone), anti-transferrin receptor 1:1000 (Life 
Technologies), anti-β-actin 1:5000 (Sigma) and anti-FGF13 1:200.78  Blotting for β-actin 
demonstrated if intracellular proteins had been biotinylated and those replicates were not 
quantified if the biotinylated fraction was positive.  Transferrin receptor was used as a 
surface loading control.   
3.3.11 Statistical analyses 
Results are presented as means ± standard error of the mean; statistical 
significance of differences between groups was assessed using one-way analysis of 
variance (ANOVA) with Fisher’s Least Significant Difference as a post-hoc test.  The cut 
off for statistical significance was set at P < 0.05.   
Table 7: Normal Tyrode Bath Solution 
  FW mM g/1 L 
NaCl 58.44 140 8.18 
KCl 74.56 5.4 0.40 
CaCl2·2H2O 147.00 1 0.15 
MgCl2·6H2O 203.31 1 0.20 
HEPES 238.30 5 1.19 
D-glucose 180.16 10 1.80 
pH to 7.2 with 1 N NaOH 
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Table 8: External ICa Recording Solution 
  FW mM g/1L 
NMDG 195.21 150 29.28 
HEPES 238.3 10 2.38 
CsCl 165.7 2 0.33 
CaCl2·2H2O 147.01 2 0.29 
MgCl2·6H2O 203.30 1.2 0.24 
4-aminopyridine 94.12 2 0.19 
D-glucose 180.16 5.5 0.99 
pH to 7.2 with 12 N HCl 
 
Table 9: ICa Pipette Solution 
  FW mM g/1L 
CsOH·H2O 149.91 70 1.05 
Aspartic acid 133.10 80 1.06 
CsCl 168.36 40 0.67 
NaCl 58.44 10 0.06 
MgCl2·6H20 203.30 2 0.04 
HEPES 238.30 10 0.24 
EGTA 380.35 10 0.38 
MgATP 551.10 5 0.28 
Na2GTP 523.30 0.2 0.01 
Na2phosphocreatine 354.10 4 0.14 
pH to 7.2 with 1 N CsOH 
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Table 10: Current Clamp Pipette Solution 
  FW mM g/100 ml 
KCl 74.55 110 0.82 
NaCl 58.44 5 0.03 
MgATP 551.10 5 0.28 
Na2phosphocreatine 354.10 5 0.18 
Na2GTP 523.30 1 0.05 
HEPES 238.30 10 0.24 
pH to 7.2 with 1 N KOH 
   
3.4 Results 
3.4.1 Junctophilin-2 is in complex with FGF13 
Although we previously showed that FGF13 is an intracellular modulator of 
voltage-gated Na+ channels,78 close analysis of FGF13 immunocytochemistry in adult rat 
cardiomyocytes revealed an overall distribution that extended beyond what has been 
reported for NaV1.5 in heart.
39 Specifically, we observed a striated pattern similar to a T-
tubule distribution (see Figure 20A, inset), in addition to the sarcolemmal and nuclear 
distribution we previously reported.78  This led us to hypothesize that FGF13 may have 
roles in cardiomyocyte physiology beyond NaV1.5 regulation.  To identify other potential 
FGF13 interactors, we performed immunoprecipitation using a previously validated 
FGF13 antibody or an IgG (as a control) from adult ventricular tissue and liquid 
chromatography / mass spectrometry analysis of the immunoprecipitated FGF13 protein 
complex.  One interesting candidate we identified was Junctophilin-2 (JPH2).  As shown 
in Figure 20B, we identified 4 unique peptides spanning all soluble domains of JPH2.   
We found this candidate to be of interest because it is a protein responsible for properly 
juxtaposing CaV1.2 and the Ryanodine Receptor 2 (RyR2) in the T-tubule (Figure 20B), 
consistent with the t-tubular distribution of FGF13. The specificity of the mass 
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spectrometry approach was confirmed through the identification of three FGF13 peptides 
after FGF13 immunoprecipitation, but none with the control IgG; and eight peptides (but 
none in the control IgG sample) from the known FGF13 binding partner NaV1.5 (see 
Table 11 for all peptide data). We further validated that FGF13 was in complex with 
JPH2 through co-immunoprecipitation, detecting JPH2 in FGF13 immunoprecipitates but 
not in the IgG control (Figure 20C).  
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Figure 20: FGF13 associates with JPH2 as part of the dyad macromolecular 
complex. A, immunocytochemical analysis shows FGF13 (green) in the nucleus, 
the sarcolemma and T-tubules, enlarged in the inset. DAPI is in blue. Scale bar 50 
µm. B, schematic of JPH2 indicating the putative protein motifs and the location of 
the unique peptides identified by mass spectroscopy in red. MORN motifs are 
indicated in yellow. JPH2 is found in the dyad in which CaV1.2 is juxtaposed to 
RyR2. MORN, membrane occupation and recognition nexus; α-helix, alpha helical 
domain; divergent, divergent region; TMD, transmembrane domain; SR, 
sarcoplasmic reticulum. C, representative co-immunoprecipation and western blot 
to validate the interaction of JPH2 and FGF13, repeated three times. 
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Table 11: Summary of peptides from proteomic screen 
Protein name 
# of Peptides 
Peptide Sequence 
FGF13 
IgG 
Control 
IgG 
 
Fibroblast growth factor 13 3 0 NKPAAHFLPKPLK 
FGF13_MOUSE
*
 
  
SVSGVLNGGK 
   
VVAIQGVQTK 
Sodium channel type 5 subunit  8 0 ALNQLSLTHGLSR 
alpha 
  
ALSAVSVLTSALEELEESHR 
SCN5A_MOUSE
*
 
  
DQGSEADFADDENSTAGESESHR 
   
EGLPEEEAPRPQLDLQASK 
   
ESLAAIEKR 
   
HASFLFR 
   
KPAALATHSQLPSCIAAPR 
   
TSLLVPWPLR 
Junctophilin-2 4 0 ELAPDFYQPGPEYQK 
JPH2_MOUSE
*
 
  
LLQEILENSESLLEPPER 
   
RSDSAPPSPVSATVPEEEPPAPR 
      YEGEWLDNLR 
 
* Protein accession numbers from SwissProt 2011 
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3.4.2 FGF13 knockdown perturbs dyad organization by affecting 
CaV1.2 localization   
JPH2 is a protein responsible for coordinating the interactions between the 
sarcolemma and the sarcoplasmic reticulum (SR). JPH2 has a C-terminal 
transmembrane domain in the SR and its N-terminus interacts with the inner leaflet of 
the sarcolemma, providing a means to juxtapose the sarcolemma and SR so as to 
promote efficient CICR by apposing CaV1.2 and RyR2.
147 Based on our discovery that 
FGF13 was a component of the JPH2 macromolecular complex, we tested whether 
FGF13 participated in dyad ion channel targeting. We performed immunocytochemistry 
on mouse ventricular myocytes that were uninfected (CON) or that had been infected 
with a FGF13 shRNA adenovirus targeting all FGF13 splice variants (FGF13 KD) or a 
scrambled shRNA adenovirus (SCR, Figure 21). As we previously showed (see also 
Figure 23), the KD adenovirus reduced FGF13 protein by ~ 90% and the SCR virus had 
no effect.78  In the CON and SCR, we observed α1C, the CaV1.2 pore-forming subunit, 
colocalized with RyR2 in a striated pattern. Little α1C or RyR2 was observed between the 
striations. After FGF13 KD, however, we saw a loss of colocalization and a large portion 
of α1C was now present between the RyR2 striations (Figure 21A, Pearson’s correlation 
co-efficient of 0.52 ± 0.03 versus 0.65 ± 0.03 and 0.62 ± 0.03 in CON and SCR 
cardiomyocytes, respectively; P < 0.05 for FGF13 KD versus CON or SCR 
cardiomyocytes, N=8 cells per group).   
We then performed quantitative analysis on the pattern of CaV1.2. In CON adult 
mouse cardiomyocytes (Figure 21A) or after infection with the SCR virus (Figure 21B), 
α1C displayed the expected striated pattern with a periodicity of ~ 2 µm, consistent with a 
t-tubular distribution.148 In contrast, the pattern in FGF13 KD cells was discontinuous 
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with multiple punctae found between the residual striations (Figure 21B). With the 
analyzer blinded to treatment status, we quantified the change in distribution with 
intensity profiles of α1C in confocal z-stacks of non-nuclear areas, as shown in Figure 
21B.  In SCR cardiomyocytes, we detected a regular pattern of intense α1C staining at ~ 
2 µm intervals (analyzed by fast Fourier transform, Figure 21D), with almost no signal in 
the intervening intervals. In contrast, after FGF13 KD, the peak amplitude of α1C staining 
at the ~ 2 μm interval was reduced by more than 50% (FFT amplitudes (in arbitrary 
units): CON 0.284 ± 0.017 (n=8), SCR 0.234 ± 0.009 (n=8), FGF13 KD 0.116 ± 0.020 
(n=12); P < 0.0001 for FGF13 KD vs. SCR and CON), and significant α1C signal was 
observed in between the peaks (Figure 21B, D). 
We tested whether this altered α1C distribution was secondary to a general defect 
in T-tubule architecture or was more specific to α1C using two separate analyses. First, 
we performed immunocytochemistry for the sodium-calcium exchanger (NCX), another 
T-tubule-localized protein, and observed that FGF13 KD did not affect NCX distribution 
(Figure 21C, D).  Second, the membrane-binding dye, di-8-ANEPPS, revealed that T-
tubular distribution was grossly unaffected by FGF13 KD (Figure 21E).   
The specific change in CaV1.2 localization after FGF13 KD led us to hypothesize 
that FGF13, as a member of the JPH2 macromolecular complex anchored by JPH2, 
affected CaV1.2 targeting to T-tubules. We therefore tested whether CaV1.2 was a 
component of the JPH2 complex. Indeed, by co-immunoprecipitation, we were able to 
pull down the α1C pore-forming subunit of CaV1.2 with an antibody to JPH2 but not a 
control IgG (Figure 21F). These data are consistent with a previous observation that 
JPH2 interacts with Cav1.1 in skeletal muscle,149 but are, to the best of knowledge, the 
first demonstration of an interaction between JPH2 and an L-type Ca2+ channel in in 
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cardiac muscle.   Together, these data indicated that FGF13 KD did not affect T-tubule 
or SR architecture, but FGF13 has a specific role in targeting CaV1.2 to its proper T-
tubular location. 
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Figure 21: FGF13 perturbs dyad organization and CaV1.2 localization.  A, 
RyR2 is unaffected by FGF13 knockdown and CaV1.2 no longer colocalizes with 
RyR2 (p < 0.05, see text for numbers). B, intensity plots for α1C were drawn of a 15 
µm x 5 µm area of the cell. Similar studies were done for sodium-calcium 
exchange (NCX), C. D, the interval distance was calculated using a FFT for α1C 
(left) and NCX (right). Amplitudes for α1C were 0.28 ± 0.02, 0.23 ± 0.01 and 0.12 ± 
0.02 for control, scrambled and shRNA respectively.  P < 0.001 for FGF13 KD vs. 
CON (not shown) or SCR. C (right), NCX is not affected by FGF13 knockdown, 
(p=0.40 for n=10 per group).  Scale bar 5 µm for A, B, and C. E, Di-8-ANEPPS 
staining of T-tubules showed no change in morphology. Scale bar 20 µm, n=20, 10 
and 14 for CON, SCR, and KD respectively. F, representative co-
immunoprecipitation and western blot of the pore-forming α1C subunit of CaV1.2 
with JPH2 from mouse ventricular lysate from three independent experiments 
showing an interaction with an antibody specific to JPH2 but not the IgG control. 
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3.4.3 FGF13 modulates CaV1.2 trafficking to the surface and current 
density 
We hypothesized that this aberrant CaV1.2 localization would lead to a decrease 
in CaV1.2 at the surface.   We therefore quantified the relative amount of CaV1.2 at the 
sarcolemma after FGF13 KD by labeling surface proteins with biotin and capturing them 
with avidin beads after cell lysis.  Both the surface fraction and the whole cell lysate of 
adult mouse ventricular myocytes were then probed with an antibody against the pore-
forming α1C subunit of CaV1.2. These biotinylation experiments revealed a decrease in 
amount of α1C at the surface after FGF13 KD (Figure 22A-B). The total amount of α1C (in 
the cellular lysate) was unchanged.  To test whether this decreased CaV1.2 at the 
surface, led to physiologic changes, we measured Ca2+ channel current density using 
whole-cell patch clamp. In FGF13 KD cardiomyocytes, but not the SCR cardiomyocytes, 
Ca2+ channel current density was reduced by 35% compared to CON cardiomyocytes 
(Figure 22C, D).  Channel availability, voltage-dependence of activation and steady-state 
inactivation, were unaffected (Table 12). Together, these results suggest that FGF13 
knockdown reduced Ca2+ current density by affecting the number of channels at the 
sarcolemma. 
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Figure 22: FGF13 affects CaV1.2 surface expression and current density. 
Surface expression of CaV1.2 is reduced with FGF13 KD while total protein 
remains unchanged in surface biotinylation and western blotting, A.  Summarized 
data of four independent biotinylation experiments in B. C, representative ICa 
traces from voltage-clamp of mouse ventricular cardiomyocytes (voltage protocol 
shown below).  D, summarized IV curve. * P < 0.05 for n=11, 6 and 14 for CON, 
SCR, and KD respectively. 
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3.4.4 Human FGF13VY can rescue CaV1.2 current density and 
localization 
To confirm a role for FGF13 in targeting CaV1.2 to the T-tubules and regulating L-
type Ca2+ channel current density, we performed “rescue” experiments on adult rat 
ventricular cardiomyocytes treated with FGF13 shRNA by co-expressing human, 
shRNA-insensitive and Hisx6-tagged, FGF13-VY (hFGF13-VY). FGF13 is differentially 
spliced at its N-terminus76 and we chose this FGF13 splice variant for rescue because it 
is the most highly expressed isoform in mouse and rat cardiomyocytes.78 The 
adenovirus expressing FGF13 shRNA also expressed GFP (via a CMV promoter) and 
the adenovirus expressing hFGF13-VY also expressed mRFP, allowing us to identify 
cells in which hFGF13-VY was expressed in the context of endogenous FGF13 
knockdown (Figure 23A). Immunostaining for endogenous FGF13 (with an anti-FGF13 
antibody) and hFGF13-VY (with an anti-Hisx6 antibody) demonstrated not only effective 
knockdown of endogenous FGF13 but also that the expressed hFGF13-VY recapitulated 
the overall cellular distribution of endogenous FGF13 (Figure 23A), although the striated 
pattern was even more obvious when compared to endogenous FGF13. We suspected 
that the subtle differences in pattern reflected the specific distribution of hFGF13-VY 
compared to the distribution of all endogenous splice variants recognized by the 
antibody in CON cells. 
Having established the efficacy of the hFGF13-VY rescue, we examined CaV1.2 
Ca2+ current density in adult rat ventricular myocytes using whole-cell patch clamp. As in 
mouse cardiomyocytes (Figure 22C), FGF13 knockdown reduced CaV1.2 Ca
2+ channel 
current density (Figure 23B, Table 12). Expression of hFGF13-VY restored Ca2+ current 
density to wild-type levels (Figure 23B). We also noted a hyperpolarizing shift in steady-
state inactivation compared to CON cells (Table 12). The reasons for this are unclear, 
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but may result from the overexpression of the specific FGF13-VY splice variant in the 
context of the knockdown of other FGF13 splice variants, thus altering any 
counterbalancing effects imparted by these absent variants. Additionally, the cellular 
distribution of α1C was restored with FGF13-VY overexpression, as indicated by the 
overall pattern and by Fourier transform (Figure 23C, D). This rescue strategy therefore 
firmly established a role for FGF13 in targeting CaV1.2 to T-tubules and provided a 
potent confirmation of the specificity of the FGF13 KD virus. 
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Figure 23: Human FGF13-VY rescues CaV1.2 current density and 
localization.  A, immunocytochemistry showing endogenous FGF13 and the level 
of knockdown with adenovirus expressing GFP and shRNA to all FGF13 splice 
variants (top two panels).  Overexpression of shRNA-resistant, hFGF13-VY (also 
expressing mRFP) in the bottom panel. Scale bar 40 µm. hFGF13-VY rescued 
decreased current density (B) and the change in α1C localization (C, D) seen with 
FGF13 knockdown (KD). Scale bar 5 µm. Fast Fourier transform amplitudes were 
CON, 0.27 ± 0.01 (n=5), FGF13 KD, 0.15 ± 0.24 (n=6) and FGF13 KD + hFGF13-VY, 
0.27 ± 0.04 (n=5), P < 0.001 for FGF13 KD compared to CON and FGF13 KD + 
hFGF13-VY. *P < 0.05 for FGF13 KD vs. control and FGF13 KD + hFGF13-VY. 
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3.4.5 FGF13 affects Ca2+ transients but preserves excitation-
contraction coupling gain 
The mislocalization of CaV1.2 after FGF13 knockdown, the newly described 
interaction between FGF13 and JPH2, and previous studies that defined clear roles for 
JPH2 in Ca2+ induced Ca2+ release (CICR)72 prompted us to query whether FGF13 
influenced excitation-contraction (EC) coupling gain.  We therefore simultaneously 
recorded Ca2+ currents and Ca2+ transients in CON, SCR, and FGF13 KD rat ventricular 
myocytes (Figure 24). Following a previously described protocol to ensure steady-state 
CaV1.2 function,
72 we held the cells at -40 mV to inactivate Na+ channels and gave a 500 
ms pulse to 0 mV to induce influx of Ca2+ through CaV1.2 and recorded it via whole-cell 
patch clamp.  We simultaneously recorded Ca2+ transients using Fura-2 in the pipette 
internal solution.  Representative traces are shown in Figure 24A.  Knockdown of FGF13 
not only reduced Ca2+ current through CaV1.2 (Figure 24B), as previously shown, but 
also led to decreased Ca2+ release from the sarcoplasmic reticulum (SR, Figure 24C).  
Interestingly, it appeared that those channels that were at the surface were coupling with 
RyR2 appropriately as EC-coupling gain was not different between the groups.  These 
changes were not due to decreased SR load as measured by rapid application of 
caffeine in Fura-2 loaded cells (peak height 0.28 ± 0.05 Δ340/380 (n=5), 0.32 ± 0.03 
Δ340/380 (n=12), and 0.29 ± 0.03 Δ340/380 (n=14) for CON, SCR, and KD respectively, 
p=0.66). These data indicated that decreased Ca2+ transients after FGF13 KD were at 
least partially due to decrease current through CaV1.2 and are consistent with its 
discovered interaction with JPH2, a known regulator of this function. 
 93 
 
Figure 24: FGF13 knockdown reduces Ca2+ transients but preserves EC-
coupling gain. A, representative traces of simultaneous whole-cell voltage clamp 
of Ca2+ current and Ca2+ transient recordings.  B-D, summarized data for the 
labeled measurements. * P < 0.05 for KD vs SCR (n=10 per group). 
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3.4.6 FGF13 affects multiple phases of the cardiac action potential 
Having established that FGF13 modulates not only voltage-gated Na+ channels,78 
but also CaV1.2 Ca
2+ channels and Ca2+ transients, we hypothesized that loss of FGF13 
would have measurable effects on the cardiac action potential. Therefore, using current 
clamp, we recorded evoked action potentials in CON, SCR, or KD adult rat ventricular 
cardiomyocytes (Figure 25A-D). In FGF13 KD cells, the action potential peak amplitude 
decreased by about 20% (Figure 25A, B), consistent with the previously defined effects 
of FGF13 on the cardiac Na+ channel current.78 Additionally, we also observed a 
shortening of the action potential half-width (Figure 25A, C) (control 18.60 ± 3.34 ms 
(n=7), scrambled shRNA 17.41 ± 3.40 ms (n=5), FGF13 shRNA 9.85 ± 1.34 ms (n=7), p 
< 0.05 for FGF13 KD vs. SCR and CON).  These data are consistent with changes in 
phase 2 of the cardiac action potential that is predominantly mediated by CaV1.2 and 
implicate FGF13 as a potent regulator of Na+ and Ca2+ channels in cardiac myocytes, 
leading to changes in the cardiac action potential. 
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Figure 25: FGF13 affects the cardiac action potential.  A, induced action 
potentials in rat ventricular cardiomyocytes in current clamp mode at 1 Hz. B, 
normalized induced action potentials to emphasize the change in half width with 
FGF13 shRNA.  C, D, Summarized data of action potential amplitude and half 
width. The number of cells analyzed is indicated in parentheses. * P < 0.05, ** P < 
0.01. 
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Table 12: Summary of electrophysiology data 
  
ICa peak at 0 
mV (pA/pF) 
V1/2 of 
activation 
(mV) 
k of 
activation 
(pA/mV) 
V1/2 of 
inactivation 
(mV) 
k of 
inactivation 
(pA/mV) 
Mouse 
Cardiomyocytes      
 
Control 
 
-4.20 ± 0.51 
(11) 
-10.27 ± 1.51 
(11) 
5.43 ± 0.21 
(11) 
-29.12 ± 1.21 
(6) 
5.59 ± 0.20 
(6) 
 
Scrambled shRNA 
-4.01 ± 0.36 
(6) 
-12.16 ± 1.84 
(6) 
5.02 ± 0.37 
(6) 
-30.80 ± 1.06 
(11) 
5.44 ± 0.14 
(11) 
 
 
FGF13 shRNA 
-2.66 ± 0.36 
(14) * 
-11.50 ± 1.14 
(14) 
5.46 ± 0.15 
(14) 
-28.73 ± 1.74 
(13) 
5.39 ± 0.25 
(13) 
Rat 
Cardiomyocytes 
          
 
Control 
 
-11.61 ± 1.34 
(14) 
-12.01 ± 1.56 
(12) 
4.48 ± 0.36 
(12) 
-27.24 ± 1.23 
(9) 
4.09 ± 0.16 
(9) 
 
 
FGF13 shRNA 
 
-7.44 ± 1.38 
(11) * 
-12.43 ± 1.24 
(9) 
4.71 ± 0.29 
(9) 
-29.83 ± 1.85 
(9) 
4.42 ± 0.16 
(9) 
FGF13 shRNA + 
hFGF13-VY 
-12.57 ± 1.15 
(10) 
-11.65 ± 1.81 
(9) 
4.42 ± 0.41 
(9) 
-35.98 ± 1.91 
(7) * 
4.88 ± 0.21 
(7) * 
 
ICa indicates calcium current 
 
The number of cells analyzed for each parameter is in parentheses 
 
* P < 0.05 by ANOVA 
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3.5 Discussion 
Since the initial identification of FHFs76 their complete physiological roles have 
remained shrouded. Originally hypothesized to act as extracellular growth factors similar 
to canonical FGFs, these non-secreted FHF proteins do not appear capable of activating 
FGF receptors.138 The subsequent discovery that FHFs are binding partners for the 
intracellular CTD of voltage-gated Na+ channels80 provided context to appreciate how 
knockout of FGF14 might reduce neuronal excitability and cause ataxia in mice150 and to 
hypothesize mechanisms for SCA27, for which FGF14 was identified as the genetic 
locus.140 Our recent identification of a role for FHFs in the regulation of cardiac Na+ 
channel function and conduction78 demonstrated cardiac specific roles. Still, the cellular 
distribution of FGF13 in cardiomyocytes hinted at additional functions distinct from Na+ 
channel regulation.    
Here, we show for the first time that FHFs regulate cardiac ion channels other 
than voltage-gated Na+ channels. As such, these results fit well with our recent 
demonstration that FGF14 regulates presynaptic Ca2+ channels in cerebellar neurons.143 
Specifically, we demonstrated here that FHFs are part of the dyad macromolecular 
complex with JPH2 and CaV1.2. Through electrophysiologic and molecular biological 
methods we demonstrated that FGF13 affects Ca2+ current density and targeting of 
CaV1.2 to T-tubules.  This effect on targeting is specific to CaV1.2, and not a general 
effect on T-tubule structure, as NCX and RyR localization were not altered, nor was 
overall T-tubule structure perturbed by FGF13 knockdown.  We hypothesize that the 
abnormal localization of CaV1.2 after FGF13 knockdown represents a defect in 
intracellular sorting of these proteins in cardiomyocytes. Missorting of CaV1.2 was 
rescued by overexpression of a human FGF13 splice variant, demonstrating the 
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specificity of the FGF13 knockdown shRNA. Not only did these data provide the first 
evidence that FGF13 is required for proper targeting of CaV1.2 to the T-tubule in cardiac 
muscle, but they also show that FGF13 knockdown had profound physiologic effects on 
Ca2+ current density and Ca2+ cycling, culminating in a decrease in cardiac action 
potential amplitude and duration and a reduced Ca2+ transient amplitude in parallel with 
its reduction in CaV1.2 Ca
2+ channel current.  
The identification of JPH2 as a FGF13 interacting protein provides mechanistic 
insight to this effect. JPH2 is a structural protein found in the cardiac dyad, where the T-
tubule is juxtaposed to one terminal cisterna of the sarcoplasmic reticulum.  The 
structure of JPH2 fixes the distance between the plasma membrane and SR for efficient 
CICR (Figure 20C). JPH2 contains a cytosolic alpha helical domain that is capped on 
either side by membrane interaction motifs. On the N-terminus are multiple ‘membrane 
occupation and recognition nexus’ (MORN) motifs that interact with the inner leaflet of 
the sarcolemma. At the C-terminus is a transmembrane domain that anchors JPH2 to 
the sarcoplasmic reticulum.147  Reminiscent of our results after FGF13 knockdown, JPH2 
knockdown in cardiomyocytes affects CICR. This provides further support that the 
interaction between JPH2 and FGF13 that we observed is functionally relevant.  
Moreover, analogous to loss-of-function mutations in JPH2, we hypothesize that FGF13 
mutations may lead to “orphaned ryanodine receptors” that are no longer apposed to 
CaV1.2, and thus may be associated with heart failure.
151 Further studies in the 
appropriate model are necessary to test that hypothesis. 
Nevertheless, the phenotypes after FGF13 and JPH2 knockdown are not 
identical. JPH2 knockdown did not decrease CaV1.2 Ca
2+ current and has no reported 
effect on voltage-gated Na+ currents. Moreover, JPH2 is observed only in a striated 
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pattern in cardiomyocytes, while we observed additional FGF13 throughout the 
cytoplasm and in the nucleus. Thus, the fraction of FGF13 that interacts with JPH2 likely 
represents only one component of the overall FGF13 pool, and is likely also distinct from 
the fraction interacting with NaV1.5. Other potential FGF13 interactors have previously 
been reported, such as microtubules in neurons,152 likely indicating additional FGF13 
pools. The tubulin interaction site on FGF13 maps to a region in close proximity to where 
NaV1.5 interacts in our recent crystal structure.
43 Thus, we predict that any FGF13 
interacting with microtubules would be unable to bind NaV1.5 simultaneously, further 
underlining the concept of distinct FGF13 pools. While we have so far been unable to 
observe high affinity binding between tubulin and FGF13, the possibility of such an 
interaction in cardiomyocytes is attractive, particularly in light of the demonstration that 
CaV1.2 is trafficked along microtubules via BIN1 in ventricular myocytes.
69   
In summary, this study identified FHFs as novel modulators of the cardiac L-type 
CaV1.2 Ca
2+ channel and thereby significantly expands our understanding of the roles of 
these proteins. Our data have important clinical implications. FGF12, the dominant FHF 
in human heart (data not shown), is greater than 60% homologous with mouse FGF13. 
Our data suggest that FGF12 loss-of-function mutations would decrease both Ca2+ and 
Na+ channel currents. Since loss-of-function mutations in NaV1.5 or CaV1.2 have been 
reported in BrS,153, 154 we specifically hypothesize that FGF12 should be explored as a 
candidate locus for BrS. Only ~ 30% of BrS patients have an identified mutation,155 so 
loss-of-function mutations in FGF12 may underlie the mechanism in at least some of the 
remaining cases by nature of its ability to affect both Na+ and Ca2+ currents. 
 
 100 
3.6 Future Directions 
In this chapter, I described a novel role for FGF13 in modulating cardiac Ca2+ 
channels, however there are still many questions behind the mechanism of its 
modulation and whether/how FHFs differentially modulate Na+ and Ca2+ channels in a 
given cell. 
3.6.1 Does FGF13 directly interact with JPH2? 
While we have been able to co-immunoprecipitate FGF13 with JPH2 in 
ventricular cardiomyocytes and a heterologous expression system overexpressing both 
proteins, whether they associate through a direct interaction is unclear.    If the 
interaction is direct, we can then use biochemical tools to decipher the domain of 
interaction on both molecules.  This is clinically interesting question as mutations in 
JPH2 lead to hypertrophic cardiomyopathy.74  If these mutations lie in the interaction 
domain with FHFs and a change in their binding affinity, FHFs might contribute to the 
pathophysiology of hypertrophic cardiomyopathy.   
Additionally, with the previously published crystal structures of FHFs alone,79, 138 
and in complex with NaV1.5 and calmodulin,
43 knowledge of the interaction site can help 
us determine if JPH2 competes with the NaV1.5 CTD for binding or if it likely binds to a 
separate pool of FHF in the cell. Because JPH2 and NaV1.5 are in separate 
microdomains within the cardiomyocyte, I hypothesize the domain of interaction is 
different.   
3.6.2 How does FGF13 modulate CaV1.2 targeting to the T-tubule 
membrane? 
It remains unclear whether FGF13 binding to JPH2 is actually responsible for its 
modulation of CaV1.2.  While there is overlap in phenotype with loss of JPH2 or FGF13 
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(mislocalization of CaV1.2 compared to RyR with reduced CICR), van Oort et. al.
72 did 
not see any reduction in CaV1.2 current with JPH2 knockdown.  I hypothesize that 
FGF13 might be the link between CaV1.2 and JPH2 because in heterologous expression 
systems, co-expression of CaV1.2 with various FGF13 splice variants effects current 
density and channel kinetics.  Specifically, FGF13-S increases current density without 
affecting steady-state inactivation, whereas FGF13-VY does not affect current density 
but shifts steady-state inactivation in a depolarizing direction (data not shown).  
In order to answer this question, and begin to separate the differences in Na+ and 
Ca2+  modulation, using the crystal structure of FGF13 and the NaV1.5 CTD in our lab, 
Chaojian Wang has designed an FGF13 that is incapable of binding to NaV1.5 as tested 
by isothermal titration calorimetry and co-expression/co-purification studies.  Using the 
rescue system I established in this chapter, we can determine whether this FGF13 can 
rescue the electrophysiologic phenotypes of the Na+ channel described in the 
introduction (decreased current density, decreased availability, slower recovery from 
inactivation) and the Ca2+ defects described in this chapter (decreased Ca2+ current 
density and mislocalization of the channel).  If for example, the current density and 
surface expression of the Na+ channel can be rescued, but the availability of the channel 
cannot, one can deduce that the binding is necessary for channel kinetics but not for 
surface expression and that a more general mechanism of trafficking might be at play for 
the two ion channels.  If concomitant measurement of Ca2+ channel current density and 
localization is unchanged, that will provide further evidence that Na+ and Ca2+ channel 
trafficking occurs through a different mechanism than modulation of Na+ channel 
kinetics.  If all of the Na+ channel phenotype cannot be rescued, but all of the Ca2+ 
channel can, then it is likely that these channels are being modulated by FHFs through 
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completely separate mechanisms.  This, taken together with JPH2 binding data can help 
to demonstrate the role of FHFs in the dyad as compared to the intercalated disc and 
sarcolemma.  I hypothesize that there is a general mechanism of trafficking that FHF 
utilizes for both channels. NaV1.5 has Ankyrin-G as its structural marker of where in the 
cell it should be.  JPH2 is similar for CaV1.2.  Therefore, I hypothesize that FHFs are 
responsible for getting the channels to their structural partners, which then further 
delineate proper localization.   
3.6.3 FGF13 decreases Na+ and Ca2+ channel surface expression, but 
does not change protein levels; where are all the channels? 
In both studies of FGF13 modulation of Na+ and Ca2+ channels, we showed 
decreased surface expression, but no change in total protein levels.  Additionally, using 
immunocytochemistry I showed that the Ca2+ channels were not in the typical striated 
pattern of the cardiac T-tubule, even though T-tubule structure was grossly intact.  An 
important question is what part of trafficking do FHFs take part in? Figure 26 is a 
schematic of the anterograde ion channel trafficking pathway.  FHFs can take part in 
anything from translation on the ribosome to endoplasmic reticulum and golgi export to 
transport of the vesicles along microtubules.  Indeed, data from the interaction 
proteomics experiment on FGF13 in mouse ventricle revealed multiple ribosomal 
subunits, suggesting it might take part in translation of the protein or targeting that 
protein to the proper place once it has been translated. Additionally, Wu et. al.152 showed 
that FGF13 binds to and stabilizes microtubules.  Evidence suggests that both Ca2+ and 
Na+ channels are trafficked along microtubules.69, 156  While this idea is promising, I could 
not replicate the interaction of FGF13 and tubulin in a heterologous expression system 
or cardiomyocytes.   
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To define where it is the channels are being held with FGF13 KD, 
ultracentrifugation to separate the invidual organelles with a sucrose gradient can be 
performed.  In that way, we can isolate the nucleus, the endoplasmic reticulum, the golgi 
and the plasma membrane and look at expression of the FHFs in that subcellular 
compartment and the ion channels of interest.  This will provide insight into where the 
FHFs are exerting their effects on trafficking and might even hint at how they traffic Na+ 
channels to the AIS in neurons as well. 
 
Figure 26: The anterograde vesicular trafficking pathway. Schematic 
representation of the forward trafficking pathway that de novo ion channels (white 
cylinders) traverse to reach their specific destinations. Nascent ion channel 
polypeptides are translocated to the membrane of the rough endoplasmic 
reticulum (ER), after which they are modified and move through the ER–Golgi 
intermediate compartment (ERGIC), Golgi apparatus, and trans-Golgi network 
(TGN). From the TGN, vesicles containing ion channels are loaded onto 
microtubules and are transported to their destinations. Microtubule plus-end 
binding proteins interact with scaffolding proteins specific to particular membrane 
subdomains to achieve targeted delivery of vesicular cargo. Reprinted from Heart 
Rhythm, Vol 7, Smyth JW, Shaw RM, Forward trafficking of ion channels: What the 
clinician needs to know, 8;1135-1140, copyright 2010 with permission from 
Elsevier.  
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Retrograde trafficking and endocytosis also must be considered.  It has been 
shown that the Ca2+ channel β subunits drives dynamin-dependent endocytosis of the 
channel,157 as have islet-brain 1 in neurons.  Islet-brain 2 is a member of the islet-brain 
protein family.  It has been shown to bind to FHFs158, 159 and modulate vesicle trafficking 
in neurons.160 
3.6.4 Do FHFs play a role in cardiac hypertrophy or heart failure? 
With loss of FGF13, I observed a mislocalization of the CaV1.2 Ca
2+ channel 
compared to RyR, decreased Ca2+ current density and decreased EC coupling.  
Mislocalization of Ca2+ channels relative to RyR and reduced CICR have been reported 
in multiple models of heart failure.73, 151, 161 To test whether FGF13 plays a role in heart 
failure, I was provided ventricular tissue lysate of mice that had been subjected to 
transverse aortic constriction (TAC) or sham operated by Dennis Abraham, MD from the 
laboratory of Howard Rockman, MD.  TAC mice were shown to have decreases in 
ejection fraction by at least 30% indicating that they were in heart failure.  I took the 
lysates and western blotted them to compare levels of FGF13 in sham or TAC mice.  As 
shown in Figure 27, levels of FGF13 are doubled in mice in heart failure due to TAC. 
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Figure 27: FGF13 levels are increased in heart failure.  Example of one of three 
western blots for FGF13 from sham versus TAC mice. Five TAC mice and four 
sham mice were quantified to show a doubling of FGF13 protein levels in heart 
failure.  GAPDH as loading control. 
This suggests that FHFs are important in heart failure, through what I 
hypothesize to be a compensatory mechanism as heart failure typically leads to 
reduction in channel protein function.162  In order to study this further, the proper model 
system is necessary in which FGF13 is knocked out and we can test the response to 
TAC-induced heart failure on whole-animal physiology compared to wild-type controls.  
Unfortunately, FGF13 -/- mice are embryonic lethal at day E10.5 and exhibit large 
pericardial effusions.  Because FGF13 is found on the X-chromosome (in mice and 
humans), the FGF13 X/- females are actually mosaics due to random X-inactivation.  
While they do display a post-partum cardiomyopathy, they are not a proper system to 
study FHFs in heart failure.  Eric Q. Wei, a MD-PhD student in the Pitt lab, is designing a 
mouse with the FGF13 locus floxed, mouse such that these mice can be crossed with a 
cardiac-specific Cre-recombinase mouse to create organ-specific knockout. This will 
provide the model necessary to study FHFs in heart failure in greater detail. 
3.6.5 Do FHFs play a role in inherited cardiac arrhythmias? 
I showed that loss of FGF13 in ventricular cardiomyocytes has profound effects 
on action potential peak height and half width, correlating with the decrease in Na+ and 
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Ca2+ current density demonstrated.  As described in section 1.5.3, the effects of FHFs on 
Na+ channel currents and availability would predict loss of function mutations would lead 
to a BrS phenotype due to a loss of the action potential dome and increased transmural 
dispersion due to loss of Ca2+ and Na+ channel function.163  In the next chapter, I will 
demonstrate the effects of a FHF mutation leading to BrS on Na+ and Ca2+ currents and 
action potential morphology.   
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4. FGF12 is a novel Brugada syndrome locus 
For this study, we collaborated with Michael J. Ackerman at the Mayo Clinic in 
Minnesota to identify patients with mutations in FHFs that lead to BrS.  The following is a 
physiologic study of a single mutant in FGF12 in a patient with BrS.  It is currently in 
preparation for submission to Circulation. 
 
Jessica A. Hennessey, Cherisse A. Marcou, Chuan Wang, Eric Q. Wei, Chaojian 
Wang, David J. Tester, Margherita Torchio, Federica Dagradi, Lia Crotti, Peter J. 
Schwartz, Michael J. Ackerman, Geoffrey S. Pitt, FGF12 is a novel Brugada syndrome 
locus. Circulation. In submission. 
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4.1 Summary 
Background: Less than 30% of Brugada syndrome (BrS) cases have an 
identified genetic cause. Of the known BrS-susceptibility genes, loss-of-function 
mutations in SCN5A or CACNA1C and their auxiliary subunits are most common.  
Based on the recent demonstration that fibroblast growth factor homologous factors 
(FHFs; FGF11-FGF14) regulate cardiac Na+ and Ca2+ channel currents, we 
hypothesized that FHFs are candidate BrS loci. 
Methods and Results: We identified FGF12 as the major FHF expressed in 
human ventricle and used a candidate gene approach to query a phenotype-positive and 
genotype-negative BrS biorepository. We identified a single missense mutation in 
FGF12-B (Q7R-FGF12), among 102 subjects.  Biochemical assays demonstrated this 
mutant reduced binding to the NaV1.5 C-terminus, but not to Junctophilin-2, which 
mediates Ca2+ channel regulation. We then developed a novel adult rat ventricular 
cardiomyocyte system to query the effects of the mutation on multiple ionic currents in 
their native milieu and on the cardiac action potential. We replaced the endogenous FHF 
with human wild-type- or Q7R-FGF12 and using whole-cell patch clamp, demonstrated 
that the mutant reduced Na+ channel current density and availability without affecting 
Ca2+ channel function.  Further, the mutant, but not wild-type FGF12, reduced action 
potential amplitude, consistent with the mutant-induced loss of Na+ channel function. 
Conclusions: These multilevel investigations strongly suggest that Q7R-FGF12 
is a disease-causing BrS mutation. Moreover, these data demonstrate for the first time 
that FHF effects on Na+ and Ca2+ channels are separable. Most significantly, this study 
establishes a new method to analyze effects of human arrhythmogenic mutations on 
cardiac ionic currents.  
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4.2 Introduction 
Brugada syndrome (BrS) is a life-threatening inherited cardiac arrhythmia 
characterized by ST-segment elevation in the right precordial leads of the 
electrocardiogram (ECG).155 BrS is a channelopathy. The most commonly mutated locus 
is SCN5A, which encodes the pore-forming subunit of the major cardiac voltage-gated 
Na+ channel, NaV1.5, responsible for the phase 0 upstroke of the ventricular action 
potential. BrS mutations in SCN5A lead to a loss of function in NaV1.5, through a 
decrease in channel availability or surface expression.164 Mutations have also been 
found in the CACNA1C-encoded pore-forming subunit of the cardiac CaV1.2, L-type Ca
2+ 
channel; these mutations are also loss-of-function.98, 153  In addition to loci encoding ion 
channel pore-forming subunits, genes associated with BrS include those encoding 
channel modulatory proteins such as β subunits of both the Na+ and Ca2+ channels, as 
well as proteins responsible for their trafficking and targeting to the proper location within 
the cardiomyocyte. For most BrS patients, however, genetic analysis does not identify a 
cause, suggesting the existence of additional, yet unidentified BrS loci. 
Among candidate ion channel modulatory subunit genes are those encoding 
fibroblast growth factor (FGF) homologous factors (FHFs; FGF11-14), which can 
modulate both voltage-gated Na+ and Ca2+ channels.78, 165, 166  FHFs are part of the FGF 
superfamily, but are not secreted, cannot bind or activate FGF receptors, and do not 
function as growth factors.138 Instead, FHFs remain intracellular where they perform 
multiple tasks. Their best characterized intracellular binding partner is the C-terminal 
domain (CTD) of voltage-gated Na+ channels.80  Knockdown of the predominant FHF 
expressed in murine ventricular myocytes, FGF13, leads to decreased Na+ channel 
current density and channel availability in isolated ventricular cardiomyocytes, and a 
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reduction in conduction velocity in a myocyte monolayer.78 Additionally, FGF13 
knockdown reduces CaV1.2 current density and prevents proper targeting of CaV1.2 
channels to the T-tubule.165  
Because FHFs modulate two cardiac ionic currents that, when perturbed, lead to 
BrS, we hypothesized that loss-of-function mutations in FHFs would be associated with 
BrS. To test this hypothesis, we identified the major FHF expressed in human ventricle, 
the “B” splice variant of FGF12, and then applied a candidate gene approach to patients 
with phenotype-positive but heretofore genotype-negative BrS. Among 102 unrelated 
patients with BrS, we found a single, rare missense mutation in FGF12-B (Q7R-FGF12). 
To test the physiological effects of Q7R-FGF12, we developed a system to query the 
effects of the Q7R or WT FGF12 in an adult cardiomyocyte by replacing the endogenous 
FGF13 with the human variants. With this novel approach, we showed that the Q7R-
FGF12 mutation leads to a Na+ channel loss-of-function phenotype consistent with BrS, 
thereby identifying FGF12 as a new BrS locus.  
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4.3 Materials and Methods 
4.3.1 Study Population 
The study population consisted of 102 unrelated patients with BrS who were 
referred to either the Molecular Cardiology Laboratory, Fondazione IRCCS Policlinico 
San Matteo, Pavia Italy or to the Windland Smith Rice Sudden Death Genomics 
Laboratory at Mayo Clinic, Rochester, Minnesota for laboratory-based genetic testing.  
All BrS patients included in this study remained genotype negative after comprehensive 
genotyping for mutations in the fourteen known BrS-susceptibility genes listed here: 
SCN5A, GPD1L, CACNA1C, CACNB2B, SCN1B [including the alternatively spliced 
exon 3A; SCN1Bb], SCN3B, KCNE3, KCNJ8, KCND3, CACNA2D1, MOG1 and HCN4, 
KCNE1L and SLMAP.  This study was approved by both the Mayo Foundation 
Institutional Review Board and the Medical Ethical Committee of Fondazione IRCCS 
Policlinico San Matteo.  Informed consent was obtained for all patients. 
4.3.2 Mutational Analysis and Control Population 
Comprehensive open reading frame/splice site mutational analysis of all amino 
acid coding exons and intron borders of FGF12 was performed using polymerase chain 
reaction (PCR), denaturing high performance liquid chromatography (DHPLC), and DNA 
sequencing as previously described.167 PCR primer sequences and PCR / DHPLC 
conditions are available upon request.  
In order to be considered as a putative pathogenic mutation, any FGF12 variant 
had to be i) non-synonymous and ii) absent among at least 1000 ethnically-matched 
controls obtained from the European Collection of Cell Cultures (HPA Culture 
Collections, UK), the Human Genetic Cell Repository sponsored by the National Institute 
of General Medical Sciences and the Coriell Institute for Medical Research (Camden, 
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New Jersey), and from the Blood Transfusional Centre in IRCCS Policlinico San Matteo 
of Pavia (Italy) and all available online databases, including the 1000 Human Genome 
Project database168, 169 (www.1000genomes.org/ensembl-browser, n=1094 individuals; 
381 Caucasian; 246 African-American, 286 Asian, and 181 Hispanic), the NHLBI GO 
Exome Sequencing Project170  (http://evs.gs.washington.edu/EVS/, n=5379 individuals; 
3510 Caucasian and 1869 African-American), and the Exome Chip Design171 
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design, n=12000 individuals).  
Mutations were annotated using the single letter nomenclature whereby F45M for 
example denotes a non-synonymous variant producing a missense mutation involving a 
substitution of Phenylalanine (F) by a methionine (M) at amino acid position 45. 
4.3.3 Subcloning and adenovirus production 
Human FGF12-B (accession no. NM_004113.5) in pIRES2-AcGFP81 was 
mutated using Quickchange II Site-directed Mutagenesis (Agilent Technologies) to form 
Q7R-FGF12 and then both were subcloned into the pAdRFP adenovirus shuttle vector. 
The adenoviruses expressing FGF13 shRNA with GFP has been previously described.78 
WT-FGF12 and Q7R viruses were generated similarly using the AdEasy System 
(Agilent). The adenoviral plasmid was packaged in HEK293 cells. The recombinant virus 
was isolated by multiple freeze/thaw cycles, further amplified and then purified and 
concentrated using Vivapure Adenopack 20 (Sartorius Stedim Biotech). The viral titer 
was determined using optical density. All constructs were confirmed by sequencing.  
4.3.4 HEK293T cell transfection, electrophysiology and co-
immunoprecipitation 
Transfection, NaV1.5 Na
+ current recording with FGF12-B and 
immunoprecipitation techniques have been previously described in HEK293T cells.81 
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The construct encoding wild-type human JPH2 was generously provided by Xander 
Wehrens (Baylor College of Medicine, Houston, TX). 
4.3.5 Cardiomyocyte isolation 
Animals were handled according to National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. The study was approved by Duke University 
Animal Care and Welfare Committee. Cardiomyocytes were isolated from 6-8 week old 
Sprague Dawley rats and cultured as previously described.78  
4.3.6 Cardiomyocyte electrophysiology 
Ca2+ currents (ICa) and Na
+ currents (INa) were recorded using the whole-cell 
voltage-clamp technique in cardiomyocytes after 36 to 48 hours as previously 
described.78, 172 Cardiac action potentials were recorded in current clamp as previously 
described.172 Input resistance was not different between the groups and junction 
potential was calculated to be 5.6 mV and not corrected.  
4.3.7 Surface biotinylation and western blotting 
Surface biotinylation and western blotting were performed as previously 
described.78  
4.3.8 Immunocytochemistry 
Immunocytochemistry was performed as previously described.172 
4.3.9 Statistical analysis 
Results are presented as means ± standard error of the mean; statistical 
significance of differences between groups was assessed using one-way analysis of 
variance (ANOVA) and was set at P < 0.05.  
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4.4 Results 
4.4.1 FGF12, the most highly expressed FHF in human ventricle, is a 
BrS candidate locus 
As summarized in Figure 28, we have shown that, in adult ventricular 
cardiomyocytes, FHFs regulate NaV1.5 trafficking and function; and CaV1.2 targeting to 
T-tubules, likely through a junctophilin-2 (JPH2)-mediated process.78, 165 This prompted 
us to hypothesize that loss-of-function mutations in FHFs could perturb NaV1.5 and/or 
CaV1.2 function and lead to BrS. To determine the complement of FHFs expressed in 
human ventricle, we extracted mRNA from non-failing human ventricular tissue and 
performed quantitative reverse-transcriptase polymerase chain reaction (qPCR) for all 
FHF splice variants (see Table 13 for primer sequences). Each of the four FHFs 
undergoes alternative splicing of their first exon, which confers unique Na+ channel 
modulatory properties.82 Summarized in Figure 28B, qPCR demonstrated that FGF12-B 
is the most highly expressed FHF splice variant. There was a negligible amount of 
FGF12-A. FGF13-Y and/or FGF13-VY (the qPCR strategy cannot distinguish between 
these two variants) mRNAs were also detected, at ~ 40% of the amount of FGF12-B.  
We therefore screened 102 unrelated BrS patients in whom genetic testing had 
not detected a known BrS locus for FGF12 mutations. Clinical demographics of the BrS 
genotyope negative study cohort are shown in Table 14.  Overall, the majority of our 
cohort were male (82%), of Caucasian descent (100%) with a mean age at diagnosis of 
45 ± 13 years and a mean QTc of 407 ± 27 ms.  Forty-six patients (45%) had a 
spontaneous type 1 Brugada ECG pattern at baseline, 50 patients (49%) had a type 1 
Brugada ECG pattern induced after intravenous injection of a sodium channel blocker, 
and 6 patients had a type 1 Brugada ECG pattern with fever (6%).  Of the 102 patients in 
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the study cohort, 12 patients (12%) had a personal history and 27 patients (26%) had a 
family history of arrhythmic syncope, sudden cardiac arrest, or sudden death. 
Following comprehensive mutational analysis of FGF12, one novel putative 
pathogenic missense mutation, resulting in a substitution of glutamine (Gln,Q) at amino 
acid residue 7 by arginine (Arg, R), Q7R-FGF12, was identified in our cohort of genotype 
negative/phenotype positive patients with BrS.  This mutation involved a residue that is 
highly conserved across species and was absent in over 1000 ethnically matched, 
internal control individuals and all publically available whole exome databases (> 12,000 
individuals).  
The Q7R-FGF12 mutation was identified in a 61-year-old male who exhibited an 
abnormal ECG pattern suggestive of BrS during flecainide therapy for atrial fibrillation 
(AF).  He subsequently underwent a flecainide challenge that induced a diagnostic type 
1 Brugada ECG during his electrophysiology study and AF ablation.  His personal history 
revealed an episode of supraventricular tachycardia during surgery for a hiatal hernia; 
however, he had a negative family history of SCD. 
This mutant was of particular interest because it directly abuts the NaV1.5 
interaction surface and leads to a change in charge (neutral to positive) near an 
important conserved electrostatic interaction site, K9 (Fig. 28A, inset), which we had 
previously showed forms a salt bridge with E1890 in NaV1.5. Disruption of this salt 
bridge markedly reduced the affinity of FGF12 for NaV1.5 and affected the regulation of 
NaV1.5 by FGF12.
43 We therefore suspected that Q7R might adversely affect interaction 
with NaV1.5 and consequent regulation of NaV1.5 function. Because we recently 
discovered that FHFs also affect CaV1.2, we considered that the Q7R mutant might also 
perturb CaV1.2 regulation. 
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Figure 28: FHFs modulate cardiac Ca2+ and Na+ channels and FGF12 is a 
locus for BrS.  A, FHFs modulate CaV1.2 trafficking to the T-tubule in the cardiac 
ventricular myocyte through interactions with JPH2.  FHFs also bind to the NaV1.5 
CTD, modulating trafficking to the sarcolemma and channel kinetics.  Right, a 
surface rendering of the interface between the NaV1.5 CTD (blue) and FHF core 
domain (red).  Q7 (aqua) is in the same plane as the salt bridge between the NaV1.5 
CTD (E1890, yellow) and FHF core (K9, yellow).  B, FGF12-B is the most highly 
expressed FHF in human ventricle by qPCR.  C, denaturing high performance 
liquid chromatography (DHPLC) profiles (wild-type, brown trace, and Q7R, green 
trace).  D, DNA sequence chromatograms showing the nucleotide change at 
position resulting in a Glutamine (Q) to Arginine (R) substitution at position 7 
(Q7R) versus normal. E, sequence conservation across species for Q7R in 
FGF12B. F, Leads V1 and V2 of an electrocardiogram from the proband during a 
diagnostic flecainide challenge. 
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Table 13: qPCR primer pairs used for detecting FHF mRNA levels in adult 
human ventricle 
FGF 
isoforms Forward primer (5’ – 3’) Reverse primer (5’ – 3’) BP* 
FGF11 
 
CCAAGGTGCGACTGTGCG 
 
CGACGCTGGCGGTAGAGAG 
 
354 
 
FGF12-A 
 
CCGCAAGAGGCCGGTGAG 
 
CACTACACGCAGGCCCACGG 177 
 
FGF12-B 
 
GGAGAGCAAAGAACCCCAG 
 
CACTACACGCAGGCCCACGG 
 
159 
 
FGF13-S 
 
CGAGAAATCCAACGCCTGC 
 
CACCACTCGCAGACCCACAG 279 
 
FGF13-U 
 
GTTAAGGAAGTCGTATTCAGAGC 
 
CACCACTCGCAGACCCACAG 
 
155 
 
FGF13-V 
 
GCTTCTAAGGAGCCTCAGC CACCACTCGCAGACCCACAG 158 
 
FGF13-
VY 
GCTTCTAAGGTTCTGGATGAC CACCACTCGCAGACCCACAG 326 
 
FGF13-
VY/Y 
CACAGAGCCGGAAGAGCCTCAG 
 
CACCACTCGCAGACCCACAG 
 
266 
 
FGF14-A 
 
GAGCAGCCCCAGCAAGAAC 
 
GTAGAATTAGTGCTGTCATC 
 
215 
 
FGF14-B 
 
CCCAAATCAATGTGGTTTC 
 
GTAGAATTAGTGCTGTCATC 
 
211 
 
GAPDH 
 
CATCAGCAATGCCTCCTGCA 
 
CCGTTCAGCTCAGGGATGAC 
 
220 
 
*BP denotes length in base pairs 
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Table 14: Demographics of genotype-negative BrS patient cohort 
 Cohort 
Patient Demographic  
No. of Probands 102 
Age at Diagnosis (years) 45 ±13 
Range (yrs) 9-81 
Males 84  (82%) 
Females 18 (18%) 
Average QTc (ms) 407 ± 27 
Average PQ Interval (ms) 169 ± 27 
Symptomatic Patients (%) 12 (12%) 
Family History of Cardiac 
Events / Unexplained 
Sudden Death (%) 
27 (26%) 
Type 1 ST-segment 
Elevation at Baseline (%) 
46 (45%) 
Type 1 ST-segment 
Elevation with Sodium 
Blockade (%) 
50 (49%) 
Type 1 ST-segment 
Elevation with Fever (%) 
6 (6%) 
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4.4.2 The Q7R mutant in FGF12-B decreases binding of FGF12-B to 
NaV1.5 CTD 
To test whether Q7R produces NaV1.5 or CaV1.2 dysregulation, we first 
overexpressed NaV1.5 in HEK293T cells with His6-tagged FGF12-B wild type (WT-
FGF12) or Q7R-FGF12 and performed co-immunoprecipitations to examine whether the 
mutant affected the interaction with the NaV1.5 CTD or JPH2. There was no difference in 
co-immunoprecipitation of WT-FGF12 or Q7R-FGF12 with JPH2, as shown in Figure 
29A. In contrast, markedly less (33 ± 7 %, n= 3, p < 0.05 ) NaV1.5 co-
immunoprecipitated with Q7R-FGF12 than with WT-FGF12 (Figure 29B-C), consistent 
with the mutant’s location at the FGF12-NaV1.5 interface (see Fig. 28A). Additionally, 
isothermal titration calorimetry with purified recombinant WT-FGF12 or Q7R-FGF12 with 
the NaV1.5 CTD showed a two-fold reduction in binding affinity (Figure 29D) for the 
mutant. These data show that Q7R-FGF12 specifically affects interaction with NaV1.5 
and suggest that functional perturbation of cardiac ion currents would likely be limited to 
NaV1.5 rather than CaV1.2. 
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Figure 29: Q7R-FGF12 decreases affinity for the NaV1.5 CTD.  A, co-
immunoprecipitation and western blot of FGF12-B WT or Q7R with JPH2 from at 
least three independent experiments.  B, co-immunoprecipitation and western blot 
of FGF12-B WT or Q7R with NaV1.5 shows reduced NaV1.5 pulled down with Q7R-
FGF12 compared to WT; * p < 0.05.  Quantified in C from at least three 
independent experiments.  D, ITC data shows a two-fold decrease (p < 0.05) in 
binding affinity for Q7R-FGF12 versus WT from three independent experiments. 
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4.4.3 Q7R-FGF12 affects NaV1.5 current density and kinetics in 
HEK293T cells 
To test the functional effects of Q7R-FGF12 on NaV1.5, we co-expressed NaV1.5 
alone or together with WT-FGF12 or Q7R and recorded Na+ currents using whole-cell 
patch clamp. When co-expressed with NaV1.5, WT-FGF12 decreased current density 
compared to NaV1.5 alone (Figure 30A, Table 15). This result was unexpected since we 
had previously shown that knockdown of FGF13 in adult ventricular cardiomyocytes 
reduced current density and trafficking of NaV1.5 to the plasma membrane. We 
considered the possibility that FGF12 and FGF13 exert distinct effects on NaV1.5, 
consistent with the isoform-specific differences in interaction between FHFs and NaV 
CTDs that we previously documented,81 and isoform-specific effects on voltage-gated 
Na+ currents previously reported,82 but observed that co-expression of FGF13 also 
reduced NaV1.5 current density (Figure 31). Nevertheless, we were readily able to 
distinguish between WT-FGF12 and Q7R-FGF12, since the degree of modulation of 
current density by Q7R-FGF12 was reduced compared to WT-FGF12 (Figure 30A). We 
also tested the effect of FGF12-WT and FGF12-Q7R on steady-state inactivation. We 
had observed that knockdown of FGF13 in adult rat ventricular cardiomyocytes induced 
a hyperpolarizing shift in the V1/2. As with measurement of current density, we could 
distinguish between WT-FGF12 and Q7R-FGF12, as WT-FGF12 induced a +4 mV shift 
in the V1/2 of steady-state inactivation, while co-expression of Q7R-FGF12 produced no 
change (Figure 30B, Table 15). Although the differences between WT-FGF12 and Q7R-
FGF12 on NaV1.5 modulation were consistent with the mutant’s reduced affinity for 
NaV1.5, as observed in Figure 29, these data suggest that HEK293T cells cannot 
recapitulate all key features of NaV1.5 modulation by FHFs previously observed in 
murine adult cardiomyocytes. 
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Figure 30: Q7R-FGF12 affects NaV1.5 current density and inactivation differently 
than WT in a heterologous expression system.  A, WT-FGF12 significantly reduces 
NaV1.5 current density, whereas Q7R-FGF12 does not; * p < 0.05 versus NaV1.5 
only.  B, WT-FGF12 significantly depolarizes the steady-state inactivation curve by 
4 mV (p< 0.05 versus NaV1.5 only).  Q7R-FGF12 is unable to shift the curve from 
control levels.   
 
Figure 31: Overexpression of FGF13 reduces NaV1.5 current density in a 
heterologous expression system.  A, representative current traces of NaV1.5 only, 
or NaV1.5 plus FGF13-VY (the most commonly expressed splice variant in 
ventricular cardiomyocytes) or FGF13-U.  B, summarized data for the peak current 
density at -30 mV (280.01 ± 32.18 pA/pF, n=11 for NaV1.5 only;  119.15 ± 17.89 
pA/pF, n=12, for NaV1.5 + FGF13-VY; 121.24 ± 22.70 pA/pF, n=10, for NaV1.5 + 
FGF13-U. * p < 0.01. 
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Table 15: Summary of electrophysiology data from recordings in HEK293T 
cells 
 INa peak at -55 
mV (pA/pF) 
V1/2 of 
activation 
(mV) 
k of 
activation 
(pA/mV) 
V1/2 of 
inactivation 
(mV) 
k of 
inactivation 
(pA/mV) 
NaV1.5 only -481.7  ±  77.1 
(6) 
-50.6 ± 2.2 
(6) 
3.1 ± 0.7 
(6) 
-87.6 ± 1.0 
(9) 
5.0 ± 0.1 
(9) 
NaV1.5 +  
WT-FGF12 
-213.1 ± 44.9 
(11) * 
-45.0 ± 1.9 
(11) 
4.1 ± 0.5 
(11) 
-83.8 ± 0.6 
(12) * 
5.1 ± 0.1 
(12) 
NaV1.5 +  
Q7R-FGF12 
-309.4 ± 101.4 
(5)  
-51.0 ± 1.4 
(5) 
3.0 ± 0.4 
(5) 
-86.4 ± 0.8 
(9) 
5.0 ± 0.3 
(9) 
INa denotes Na
+ current 
* p < 0.05 
Numbers recorded are in parentheses 
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4.4.4 A system to study FHF modulation of ion channels in their 
native milieu 
We therefore designed a system to explore the physiologic effects of FHFs in 
adult rat ventricular cardiomyocytes. Our aim was to “replace” the endogenous FGF13 
with human WT-FGF12 or Q7R-FGF12 and query the resulting effect on Na+ currents. 
We began by using our established adenovirally-mediated shRNA knockdown of FGF13 
in cultured adult rat ventricular cardiomyocytes (marked by GFP), in which we achieve a 
>50% reduction of FGF13 protein within two days in culture,78 and co-infected with a 
separate adenovirus expressing either WT-FGF12 or Q7R-FGF12 (marked by mRFP). 
We confirmed effective knockdown of the endogenous rat FGF13 and proper subcellular 
localization of expressed FGF12 by immunocytochemistry with antibodies to FGF13 or 
to the Hisx6 tag on the expressed FGF12 C-termini (Figure 32). 
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Figure 32: A system to study the effects of FGF12 on ventricular cardiomyocyte 
physiology.  Control cell stained for FGF13 in Cyan shows endogenous FGF13 
distribution in the cardiomyocyte at the intercalated disc, T-tubules and nucleus; 
magnified inset (2X) emphasizes distribution at the intercalated disc and in a 
striated pattern.  Knockdown with FGF13 using a virus that expresses GFP and 
shRNA reduces the reactivity of the FGF13 antibody, even with overexpression of 
WT-FGF12, indicating no cross-reactivity.  Using a virus expressing FGF13 shRNA 
without GFP and overexpressing WT-FGF12 (indicated by RFP), there is a 
decreased immunoreactivity for FGF13 (green) and a signal using the His6 
antibody that correlates to endogenous FGF13 expression.  A similar pattern of 
His6 immunoreactivity is observed for Q7R-FGF12.  Insets are magnified 2X to 
emphasize pattern of distribution.  Scale bar 50 μm for large images and 12.5 μm 
for inset. 
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4.4.5 Q7R-FGF12 differentially affects Na+ and Ca2+ currents in a 
ventricular cardiomyocyte 
Using whole-cell patch clamp, we recorded voltage-gated Na+ currents in 
uninfected Control (CON) cardiomyocytes, those with FGF13 knocked down (FGF13 
KD), and cells with FGF13 KD and concomitant expression of WT-FGF12 or Q7R-
FGF12 (Figure 33, Table 16). Consistent with our previous results, FGF13 KD reduced 
Na+ current density without affecting voltage-dependence of activation (Figure 33A-D, -
69.47 ± 9.03 pA/pF, n=14, for Control versus -34.45 ± 5.06 pA/pF, n=9, for FGF13 KD, p 
< 0.05) and decreased channel availability through a -4 mV shift in the V1/2 of steady-
state inactivation (Figure 33E). Co-expression of WT-FGF12 compensated for the loss of 
FGF13, significantly increasing Na+ channel current density compared to FGF13 KD or 
Control (-100.28 ± 18.69 pA/pF, n=9, p < 0.05 versus Control and FGF13 KD) and 
inducing a +6 mV shift in the V1/2 of steady-state inactivation compared to FGF13 KD 
(Table 16, Figure 33E). In contrast, co-expression of Q7R-FGF12 failed to rescue 
current density or the hyperpolarizing shift in steady-state inactivation (Table 16, Figure 
33E).  
While the diminished ability of FGF12-Q7R to rescue FGF13 KD compared to 
FGF12-WT is consistent with the mutant’s decreased binding affinity for the NaV1.5 
CTD, the augmentation of Na+ channel current density above Control cells was 
unexpected, and suggested three possibilities: FGF12 is an even more potent FHF for 
Na+ currents than FGF13; FGF12 has additional effects on Na+ currents compared to 
FGF13; or NaV1.5 is not saturated by endogenous FGF13 so that FGF12 over-
expression modulates additional NaV1.5 channels that were not regulated by a limiting 
pool of endogenous FGF13. To distinguish among these possibilities, we overexpressed 
WT-FGF12 without knocking down FGF13 and measured the effects upon Na+ current 
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density. Overexpression of WT-FGF12 did not significantly increase Na+ channel current 
density in these conditions (Figure 34), indicating that FGF12 does not exert additional 
effects on NaV1.5 beyond FGF13 and that the effects of FGF13 on NaV1.5 are saturated 
in Control cells. Thus, we conclude that FGF12 is more potent than FGF13 for 
increasing NaV1.5 at the sarcolemma. The lack of an effect of FGF12 in the presence of 
FGF13 is consistent with our previous data showing that FGF13 has a higher affinity for 
the NaV1.5 CTD than FGF12;
81 in the absence of the higher affinity FGF13 (after 
knockdown), expressed FGF12 is capable of exerting its increased potency. We also 
considered that the failure of Q7R-FGF12 to increase Na+ current density in the context 
of FGF13 knockdown could be due to a dominant negative effect, similar to effect of the 
F150S mutation in FGF14, which causes spinocerebellar ataxia 27.84 We therefore 
expressed Q7R-FGF12 without knocking down FGF13. Under these conditions, the 
effects of Q7R-FGF12 were negligible (Figure 34). These results not only rule out a 
dominant negative effect, but also support the hypothesis that endogenous FGF13 
effects are saturating in Control cells.  
As shown in Fig. 29, the Q7R mutation did not appear to affect interaction with 
JPH2, leading us to expect that the mutant would have minimal effects upon ICa. We 
tested this hypothesis with the same replacement strategy. Consistent with our previous 
data, FGF13 KD in adult ventricular cardiomyocytes reduced Ca2+ current density 
(Figure 35A-B). Adenoviral expression of WT-FGF12 rescued the effect of FGF13 KD. 
Expression of Q7R-FGF12 potentiated Ca2+ currents, increasing current density to a 
level 30% higher than Control or rescue with WT-FGF12, although this difference was 
not significantly different from WT-FGF12 (Figure 35, p=0.09).  Additionally, both WT 
and Q7R FGF12 were able to rescue CaV1.2 mislocalization observed after FGF13 
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knockdown (Figure 35C). These results indicated that FHFs modulate Na+ and Ca2+ 
currents via separable mechanisms. 
 
 
Figure 33: Q7R-FGF12 cannot rescue reduced NaV1.5 current density and 
availability from FGF13 KD while WT can.  A, representative Na+ current traces for 
the four groups tested.  B-C, I-V curve and summarized peak current data.  D, 
activation curve and E, steady-state inactivation curve; see Table 3 for 
quantification. * p < 0.05 vs. Control, ** p < 0.05 versus WT-FGF12B, † p < 0.01 
versus WT-FGF12B. 
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Figure 34: WT and Q7R FGF12 do not affect Na+ channel current density 
without FGF13 KD.  I-V curve depicting the current density for CON and those 
cells with overexpression of WT or Q7R FGF12 (peak current densities at -45 mV 
were -18.05 ± 3.02 pA/pF (n=5), -20.49 ± 3.73 pA/pF (n=10), -15.53 ± 1.96 pA/pF 
(n=7) for Control, WT-FGF12, and Q7R-FGF12, respectively, p = 0.55. 
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Figure 35: Both WT and Q7R FGF12 rescue Ca2+ current density and 
localization from FGF13 KD.  A, representative Ca2+ current traces from the four 
groups.  B, I-V curve depicting the rescue of CaV1.2 current density with WT and 
Q7R FGF12. Peak current densities at 0 mV are -13.01 ± 0.88 pA/pF (n=9) for 
Control, -8.09 ± 1.30 pA/pF (n=13) for FGF13 KD, -12.86 ± 1.50 pA/pF (n=13) for 
FGF13 KD + WT-FGF12, -17.05 ± 1.46 (n=13) for FGF13 KD + Q7R-FGF12.  C, 
immunostaining for CaV1.2, green and ryanodine receptor, red, showing that 
CaV1.2 is mislocalized with FGF13 KD and the localization is rescued with WT and 
Q7R FGF12. * p < 0.05 versus control. 
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Table 16: Summary of electrophysiology data 
ICa ICa peak at 0 
mV (pA/pF) 
V1/2 of 
activation 
(mV) 
k of 
activation 
(pA/mV) 
V1/2 of 
inactivation 
(mV) 
k of 
inactivation 
(pA/mV) 
Control -13.01 ± 0.88 
(9) 
-17.2 ± 1.79 
(9) 
4.91 ± 0.33 
(9) 
-32.41 ± 1.16 
(10) 
3.80 ± 0.18 
(10) 
 
FGF13 KD 
 
-8.09 ± 1.30 
(13) * 
-15.34 ± 0.3 
(6) 
6.17 ± 0.27 
(6) * 
-30.37 ± 0.82 
(6) 
3.90 ± 0.14 
(6) 
FGF13 KD + 
FGF12-B 
WT 
12.86 ± 1.50 
(13) 
-17.59 ± 0.84 
(13) 
5.90 ± 0.17 
(13) * 
-36.33 ± 2.19 
(7) * 
5.31 ± 0.29 
(4)  
 
FGF13 KD + 
FGF12-B 
Q7R 
-17.05 ± 1.46 
(13) * 
-15.97 ± 0.60 
(13) 
6.04 ± 0.14 
(13) * 
-36.58 ± 1.50 
(4) * 
5.21 ± 0.31 
(4) 
INa INa peak at -55 
mV (pA/pF) 
V1/2 of 
activation 
(mV) 
k of 
activation 
(pA/mV) 
V1/2 of 
inactivation 
(mV) 
k of 
inactivation 
(pA/mV) 
Control -69.47 ± 9.03 
(14) 
-62.61 ± 1.38 
(12) 
8.81 ± 0.42 
(12) 
-99.71 ± 1.39 
(15) 
6.15 ± 0.31 
(15) 
 
FGF13 KD 
 
-34.45 ± 5.06 
(9) * 
-57.07 ± 1.73 
(9) 
4.56 ± 0.53 
(9) 
-103.64 ± 
1.27 (10) * 
6.59 ± 0.26 
(10) 
FGF13 KD + 
FGF12-B 
WT 
-100.28 ± 
18.69 (9) * 
-60.79 ± 1.80 
(9) 
3.74 ± 0.46 
(9) 
-97.22 ±1.93 
(6)  
5.82 ± 0.41 
(6) 
 
FGF13 KD + 
FGF12-B 
Q7R 
-38.23 ± 4.28 
(9) * 
-61.17 ± 1.48 
(8) 
4.73 ± 0.27 
(8) 
-104.51 ± 
1.52 (12) * 
6.36 ± 0.26 
(12) 
 * p < 0.05 by ANOVA and compared to 
Control 
  
 ICa denotes Ca
2+
 current   
 INa denotes Na
+
 current   
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4.4.6 Q7R-FGF12 leads to changes in action potential morphology 
consistent with BrS 
Finally, we assessed the effects of WT-FGF12 and Q7R-FGF12 on the 
ventricular action potential. As we previously reported,165 FGF13 KD decreased the 
action potential peak amplitude and half width, consistent with observed reductions in 
Na+ and Ca2+ channels. Rescue with WT-FGF12 restored both peak amplitude and half-
width to control levels. In contrast, rescue with Q7R-FGF12 failed to restore the peak 
amplitude, consistent with its lack of efficacy in modulating NaV1.5 currents, and 
increased the half-width (Figure 36A-C), which we hypothesize results from potentiating 
effect of Q7R-FGF12 on CaV1.2 Ca
2+ current density (see Discussion). 
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Figure 36: Q7R-FGF12 recapitulates the BrS action potential.  A, 
representative evoked action potentials from cardiomyocytes of the four groups.  
B-C, summarized data for action potential peak amplitude and half width, 
respectively.  * p < 0.05 versus control, ** p < 0.01 versus control, † p < 0.01 versus 
FGF13 KD + WT-FGF12.   
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4.5 Discussion 
Inherited cardiac arrhythmias such as BrS can result from mutations in ion 
channel pore-forming subunits or their modulator proteins, providing consequent 
functional changes in ionic currents. Although still only accounting for less than 25% of 
BrS, the most commonly affected current in BrS is the voltage-gated Na+ channel, and 
most identified mutations are loss-of-function in SCN5A or in genes that encode 
regulators of NaV1.5 currents, leading to a reduction in Na
+ current density.165 Less 
commonly, loss-of-function mutations in CaV1.2 and its beta subunit have been linked to 
BrS. In this context, we suspected that loss-of-function mutations in FHFs, which we 
showed can modulate the cardiac voltage-gated Na+ and Ca2+ channels,78, 165 were likely 
BrS candidate loci. After identifying the FGF12-B splice variant as the most abundantly 
expressed FHF in human ventricle, we queried a BrS repository and discovered a Q7R 
mutation in FGF12-B that leads to a Na+ channel loss-of-function phenotype consistent 
with the BrS diagnosis, using a novel, adult ventricular cardiomyocyte system. 
By providing extensive evidence that this rare FGF12 variant is the disease-
causing mutation, we demonstrate that FGF12 is a new BrS locus. We showed that this 
mutation decreased the affinity of FGF12 for the NaV1.5 CTD; that functional regulation 
of NaV1.5 by FGF12 is adversely affected; and that ventricular action potentials are 
perturbed. We also demonstrated that Q7R-FGF12 is fully capable of modulating CaV1.2 
Ca2+ currents. Thus, this mutant appears causal for BrS in this patient due to loss-of-
function effects on Na+ channel currents. Further, these results allow for the first time a 
separation of FHF-dependent effects on Na+ channels from Ca2+ channels. Because the 
Q7R mutation is on the NaV1.5 CTD interface and affects the affinity of FGF12 for the 
CTD, these data suggest that the modulatory actions of FHFs on CaV1.2 channels result 
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from a different domain of the FHF. Although the interaction site between FHFs and 
JPH2, which is associated with the FHF-dependent effects on Ca2+ channels, has not yet 
been mapped, we hypothesize that the JPH2 interaction site is distinct from the NaV1.5 
CTD interaction site. As such, this BrS mutation will be a useful tool for further 
differentiating among distinct FHF pools within a cardiomyocyte.   
The increase in action potential half width in the context of the Q7R-FGF12 was 
unexpected but possibly reflects the potentiating effect of the mutant FGF12 on the 
cardiac Ca2+ current density (Figure 35). Use of exome sequencing combined with 
systems biology recently identified a gain-of-function mutant in CACNA1C (increase in 
Ca2+ channel current) associated with Long QT Syndrome,173 demonstrating that 
increased Ca2+ current density can produce a prolonged QT interval that would manifest 
as a longer ventricular action potential duration. Alternatively, the Q7R-FGF12 might 
have multiple effects upon NaV1.5, leading to a prolonged action potential or a decrease 
in peak amplitude as has been observed in specific individuals with “overlap syndromes” 
that result from mutations in SCN5A.174  Within these families, the same mutation (e.g., 
1795insD) can have disparate clinical and electrophysiological phenotypes.175 Similar to 
results obtained with 1795insD, we observed that overexpression of WT-FGF12 in 
HEK293T cells (Fig. 30) decreases NaV1.5 current density (loss-of-function), but 
depolarizes the V1/2 of steady-state inactivation (gain-of-function).  Additionally, although 
not significant (p = 0.09), there is a slight increase in CaV1.2 current density in 
cardiomyocytes expressing Q7R-FGF12 in the context of FGF13 KD from control or 
those overexpressing WT-FGF12 (Figure 35).  Together, these data provide evidence 
that FHFs may be involved in “overlap syndromes,” resulting in opposing effects on 
multiple ion channels depending on environmental and other genetic factors. Finally, as 
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our recent data demonstrates that FHFs are modulators of multiple ion channels, 6, 10 it is 
possible that FGF12 could affect additional ion channels or two properties of one ion 
channel, not necessarily in the same direction. 
Critical to our ability to define the pathogenesis of this FGF12 mutant was the 
development of an adult cardiomyocyte-based system for investigation. Initial studies in 
a heterologous expression system, although demonstrating differences between the WT- 
and Q7R-FGF12, did not yield mechanistic insight consistent with the disease 
phenotype. While heterologous expression systems can show changes in intrinsic 
channel properties and its regulators isolated from the complex environment of a 
cardiomyocyte, these systems cannot accurately recapitulate the ion “channelsomes” 
and are not suited to query combinations of unanticipated cardiomyocyte-specific factors 
or the particular anatomy of a cardiomyocyte (e.g., T-tubules).  Indeed, differences in 
results from a heterologous expression system and from native cell types have been 
previously reported for FHF regulation of Na+ channel currents82, 84 and likely derive from 
a requirement for aspects of the native channel environment for complete expression of 
the FHF-regulated phenotype. While induced pluripotent stem cells (iPSCs) offer a 
similar strategy for testing endogenous effects of arrhythmogenic mutations,176 the 
resulting cardiomyocytes are often immature, precluding definitive assessment of the 
adult phenotype, and iPSC technology does not currently offer a high throughput method 
for analysis of multiple mutants.  
In summary, using a native cardiomyocyte system, we demonstrated that Q7R-
FGF12, is a new BrS locus and that the mutant affects Na+ channel trafficking and 
kinetics with minimal effects on Ca2+ channel function. These results also demonstrate a 
clear separation of the effects of FHFs on Na+ channels from Ca2+ channels. Since BrS 
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and other inherited arrhythmias can result from changes in Na+ channel or Ca2+ channel 
function, we hypothesize that other mutations in FGF12 may underlie genotype-negative 
cases of inherited arrhythmias. 
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